

Evidence Synthesis

Number 44

Screening for Elevated Lead Levels in Childhood and Pregnancy: Update of a 1996 U.S. Preventive Services Task Force Review

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract Number 290-02-0024

Task Order Number 2
Technical Support of the U.S. Preventive Services Task Force

Prepared by:

Oregon Evidence-based Practice Center
Portland, Oregon

Investigators:

Gary Rischitelli, MD, JD, MPH
Peggy Nygren, MA
Christina Bougatsos, BS
Michele Freeman, MPH
Mark Helfand, MD, MPH

Oregon Evidence-based Practice Center
Oregon Health and Science University
3181 SW Sam Jackson Park Road
Portland, Oregon 97239

December 2006

TABLE OF CONTENTS

1996 Recommendations.....	3
Methods for Updating the 1996 Report	3
Results.....	5
Key Question 1: Direct Evidence of Screening	5
Key Question 2: Prevalence; Burden of Suffering	5
Key Question 3: Accuracy of Screening Tests	11
Key Question 5: Effectiveness of Early Detection	13
Key Questions 4 and 6: Adverse Effects of Screening and Intervention.....	21
Recommendations of Other Groups.....	21
Discussion.....	23
References.....	26

TABLES

Table 1. Effects of Chelation on Children’s Blood Lead Levels
Table 2. Effects of Environmental Modifications on Children’s Blood Lead Levels
Table 3. Summary of Effects of Environmental Modifications on Children’s Blood Lead Levels
Table 4. Effects of Nutritional Interventions on Children’s Blood Lead Levels
Table 5. Summary of Nutritional Interventions on Children’s Blood Lead Levels
Table 6. Summary of the Evidence

APPENDIX

Appendix 1. U. S. Preventive Services Task Force Quality Rating Criteria
--

1996 RECOMMENDATIONS

B Recommendation:

In 1996, the Task Force recommended screening for elevated lead levels at least once at age 12 months in all children with identifiable risk factors, and in all children living in communities in which the prevalence of blood lead levels requiring individual intervention, including residential lead hazard control or chelation therapy, was high or was undefined. There was insufficient evidence, however, to recommend a specific community prevalence below which targeted screening could be substituted for universal screening.

C Recommendation:

The Task Force found insufficient evidence to recommend for or against routine screening for lead exposure in asymptomatic pregnant women.

C Recommendation:

The Task Force also found insufficient evidence to recommend for or against trying to prevent lead exposure by counseling families to control lead dust by repeated household cleaning, or to optimize caloric, iron, and calcium intake specifically to reduce lead absorption.

METHODS FOR UPDATING THE 1996 REPORT¹

Problem Formulation

Members of the USPSTF defined the scope of this update, in cooperation with the Agency for Healthcare Research and quality (AHRQ) and the Oregon Evidence Based Practice Center (EPC) personnel. The Task Force's goals for this update were to address the gaps in the literature revealed in the 1996 USPSTF recommendations.² These gaps related to the accuracy of risk assessment questionnaires in children with varying blood lead levels, the population prevalence at which to change from targeted screening to universal screening, the effectiveness of interventions to lower lead levels, and cost-effectiveness analyses of lead screening programs.

Search for New Studies

EPC personnel searched MEDLINE, reference lists of review articles, and tables of contents of leading pediatric journals for studies published in 1995 or later that contained new information about the prevalence, diagnosis, natural course, or treatment of elevated lead levels in asymptomatic children ages 1-5 and in pregnant women. Articles that met the following criteria were included in this update:

- 1) The study was an original meta-analysis, prospective cohort study, controlled trial, quasi-experimental study with concurrent controls, or case-control study; not a case series, case report, or comparison with historical controls.

- 2) The study was not included in the 1996 review.
- 3) The study was rated at least “fair-quality” using the USPSTF criteria (Appendix 1) for internal validity.

Synthesis

This report uses text and format from the 1996 report¹ on lead screening, updating the text and citations where appropriate. Members of the USPSTF and AHRQ identified critical issues for updating the 1996 USPSTF guidelines for lead screening. To prepare this update, we reviewed trials and epidemiologic studies published since January 1995 bearing on these critical issues. For the critical key questions only (see below), we used standard USPSTF methods³ to abstract information about the design, results, and internal validity of each study, and included only those studies we rated fair-quality or better. We reviewed the populations of asymptomatic children and pregnant women separately.

Key questions in the 2005 work assignment for CHILDREN were stated as follows:

- KQ1: Is there direct evidence that screening for lead results in improved health outcomes (i.e. cognitive changes, behavioral problems, learning disorders)?
- KQ2: What is the prevalence of elevated lead in children? Are there population-level risk factors that identify children at higher risk for elevated lead levels (i.e., geography, race/ethnicity, socioeconomic status, age)?
- KQ 3: Can screening tests accurately detect elevated blood lead levels? What is the accuracy of using questionnaires (or other tools) for risk factor assessment at various blood lead levels? What is the optimal frequency for screening? What is the optimal frequency for repeat testing?
- KQ4: What are the adverse effects of screening?
- KQ5: Do interventions (i.e. counseling families to reduce lead exposure, nutritional interventions, residential lead hazard control techniques, chelation therapy) for elevated lead levels result in improved health outcomes?
- KQ6: What are the adverse effects of interventions?
- KQ7: What are cost effectiveness issues?

Members of the USPSTF and AHRQ identified KQs 1 and 5 as critical key questions. We therefore updated KQs 1 and 5 using standard systematic review procedures. We conducted a selected review of the literature that addressed KQs 2-4, 6, and 7.

Key questions in the 2005 work assignment for PREGNANT WOMEN were stated as follows:

- KQ1: Is there direct evidence that screening in asymptomatic pregnant women for lead results in improved health outcomes (i.e., cognitive changes in offspring, perinatal outcomes including birth weight/preterm delivery etc, maternal blood pressure)?
- KQ2: What is the prevalence of elevated lead in asymptomatic pregnant women? Are there population-level risk factors that identify pregnant women at higher risk for elevated lead levels (i.e., geography, racial/ethnicity, socioeconomic status, age)?
- KQ3: Can screening tests accurately detect elevated blood lead levels? What is the accuracy of using questionnaires (or other tools) for risk factor assessment at various blood lead levels?
- KQ4: What are the adverse effects of screening?
- KQ5: Do interventions (i.e., counseling families to reduce lead exposure, nutritional interventions, residential lead hazard control techniques, chelation therapy) for elevated lead levels result in improved health outcomes?
- KQ6: What are the adverse effects of the interventions?
- KQ7: What are cost effectiveness issues?

We used standard systematic review procedures to address KQs 1 and 5. We conducted a selected review of the literature on pregnant women for KQs 2-4, 6, and 7.

New studies or information for key questions for children and pregnant women are discussed throughout the text below using the format from the 1996 chapter for this topic.

RESULTS

Key Question 1: Screening in children and asymptomatic pregnant women

There is no direct evidence from controlled studies that screening children for elevated blood lead levels results in improved health outcomes. There is no direct evidence from controlled studies that screening improves maternal hypertension, cognitive changes in offspring or perinatal outcomes.

Key Question 2: Prevalence; Burden of Suffering

Summary: The prevalence of elevated blood lead levels among children and women in the United States, like that in the general population, continues to decline sharply, due primarily to marked reductions in lead in gasoline, air, dietary sources, and residential paint. However, the prevalence still varies substantially among different communities and populations, and children and pregnant women share many of the same risk factors for elevated blood lead. Correlates of higher blood lead levels at all ages include minority race/ethnicity; urban residence; low income;

low educational attainment; older (pre-1950) housing; home renovation or remodeling; pica; use of ethnic remedies, cosmetics, and lead glazed pottery; occupational and para-occupational exposures; and recent immigration. Alcohol use, smoking, pica, and immigration status have been demonstrated as risk factors among pregnant women.

Recent observational studies have demonstrated an inverse relationship between historical blood lead levels in children and subsequent measures of behavioral and cognitive performance at blood lead levels of <10 micro-g/dL. Recent observational studies provide limited, preliminary data that prenatal blood lead levels <10 micro-g/dL may be associated with neurodevelopmental delay or impairment. Study design and measurement issues, however, limit interpretation of these studies. Studies also suggest that levels of maternal exposure in this range may be associated with increased risk for spontaneous abortion, hypertension in pregnancy, and adverse effects on fetal growth⁴.

What is the prevalence of elevated lead in children?

The prevalence of elevated blood lead levels in the U.S. population continues to decline sharply, due primarily to marked reductions in lead in gasoline, air, dietary sources, and residential paint.⁵ In a 1999-2002 national survey of children aged 1-5 years, 1.6% had blood lead levels ≥ 10 micro-g/dL, compared to 9% in a similar survey in 1988-1991.⁶ (The units micrograms/deciliter (micro-g/dL) will be used throughout this chapter: to convert to micro-mol/L, divide by 20.72.) Although the prevalence of elevated blood lead levels among children ages 1-5 years declined by 64% from 1991-94 through 1999-2002, the prevalence still varies substantially among different communities and populations, and an estimated 310,000 children remain at risk for exposure to harmful levels of lead.⁵

What is the prevalence of elevated lead in asymptomatic pregnant women?

Blood lead levels and blood umbilical cord lead levels are frequently used to assess both the mother's and fetus' levels of lead exposure and risk. In 1992, two large surveys of low-income pregnant women found 0%⁷ and 6%⁸ with blood lead levels >5 micro-g/dL. A study of all women who enrolled in prenatal clinics in Mahoning County, Ohio, from 1990 to 1992 found that 13% of prenatal patients had blood lead levels ≥ 10 micro-g/dL, with 1% having blood lead levels greater than 15 micro-g/dL.⁹ Population mean blood lead levels in women of childbearing age and pregnant women have fallen over the past two decades. Although it was estimated in 1990 that 4.4 million women of childbearing age, and over 400,000 pregnant women, had blood lead levels of >10 micro-g/dl,¹⁰ a recent study of 1109 infants in Quebec, Canada, found a mean cord blood lead of 1.5 micro-g/dL (0.076 umol/l; 95% CI = 0.074, 0.079).¹¹ In a recent review of NHANES data of 4,394 women of child-bearing age, the GM blood lead levels 1.78 micro-g/dL¹² and a longitudinal study of pregnant women in Boston demonstrated that umbilical cord blood lead levels declined 82% between 1980 and 1990.¹³

Are there population-level risk factors that identify children at higher risk for elevated lead levels (i.e., geography, race/ethnicity, socioeconomic status, age)?

The highest geometric mean blood lead levels (GM blood lead levels) in the U.S. occur in children aged 1-5 years (GM 1.9 micro-g/dL) and in adults ≥ 60 years of age (GM 2.2 micro-g/dL), with the lowest in youth aged 6-19 years (GM 1.1 micro-g/dL).⁵ Children under 5 years of age are at greater risk for elevated blood lead levels and lead toxicity because of increased hand-to-mouth activity, increased lead absorption from the gastrointestinal tract, and the greater vulnerability of a developing central nervous system.¹⁴ Geometric mean levels are significantly higher in males than in females except among children aged 1-5 years.⁵

Correlates of higher blood lead levels at all ages include minority race/ethnicity, urban residence, low income, low educational attainment, older (pre-1950) housing, and recent immigration.^{5, 15-19} These factors are associated with increased exposure to important lead sources, including dilapidated housing with lead-based paint, lead-soldered pipes and household lead dust, and lead in dust and soil from heavy traffic and industry.²⁰⁻²⁵ There have been major reductions in the number of U.S. homes with lead-based paint from the estimated 64 million in 1990, but approximately 24 million housing units still contain substantial lead hazards, with 1.2 million of these units occupied by low-income families with young children.^{5, 26}

Other potential sources of household lead exposure include clothing or waste material brought home by workers in lead-using industries or hobbies, lead-based paint and dust contamination in pre-1978 housing undergoing remodeling or renovation,¹⁹ dietary intake from lead-contaminated consumer products, drinking water, and lead-based pottery, and traditional ethnic remedies.^{5, 27-30}

Geometric mean blood lead levels among African-American children (2.8 micro-g/dL) remain significantly higher than Mexican American children (1.9 micro-g/dL) and non-Hispanic whites (1.8 micro-g/dL). Even among low income families, however, GM blood lead levels declined significantly from 1991-1994 (3.7 micro-g/dL) to 1999-2002 (2.5 micro-g/dL).⁵

Are there population-level risk factors that identify pregnant women at higher risk for elevated lead levels?

A woman of childbearing age with a high blood lead level risks transmitting a high blood lead level to her unborn child.³¹ Ethnic background, country of origin, and immigrant status of birth mothers, as well as lifestyle, age, and work patterns of pregnant women have shown to be associated with prenatal lead exposure in newborns. Multivariate analyses of pregnant women in Quebec, Canada, revealed that both cigarette smoking (15% increase) and alcohol intake (17% increase) make significant and independent contributions to cord blood lead concentrations.³² In a survey of 10 Quebec hospitals, umbilical cord blood samples were obtained from 1,109 newborns. Although blood lead levels were considered low, a statistically significant relationship was observed between maternal age, and smoking during pregnancy, in cord blood lead concentrations.¹¹

One hundred fifty-nine mother-infant pairs from a cohort of women receiving prenatal care in Pittsburgh, Pennsylvania, provided blood samples at delivery for lead determination. Alcohol use was associated with relatively greater cord blood lead compared with maternal blood lead. No association was found with cord blood lead or maternal blood lead with smoking, physical exertion, or calcium consumption.³³

A recent study in New York City of pregnant women in their third trimester with an incident blood lead level of 20 micro-g/dL or greater showed they had newborns with a median incident blood lead level of 12 micro-g/dL. In addition, maternal blood lead levels were directly associated with gestational age and pica behavior. These cases were more than twice as likely to be foreign-born women.³⁴ Maternal immigrant status and pica behavior are also associated with high infant blood lead level.

Neurotoxic effects of lead exposure in children

Very high levels of inorganic lead exposure can produce serious neurological complications, which may result in death or long-term sequelae.^{21, 35, 36} A number of adequately designed and conducted prospective cohort studies from a broad range of child populations have reported that a rise in blood lead from 10 to 20 micro-g/dL is associated with a likely decrement of 2-3 points (reported range -6 to +1) in intelligence test scores (IQ).³⁷⁻⁴³ The variety of test instruments that have been used, and differences in adjustment for important covariates, make direct comparison of these studies difficult, but a consistent negative effect on intellectual development is reported.

In these studies, the mean blood lead levels at age 1-2 years (7.7-35.4 micro-g/dL) were higher than the current U.S. mean for this age group, but most levels were below 35 micro-g/dL. A meta-analysis⁴⁴ that included the five oldest of these cohort studies concluded that a doubling of blood lead levels from 10 to 20 micro-g/dL measured at age 2 years was associated with a statistically significant mean reduction of 1-2 IQ points; evidence was inconclusive regarding an association of IQ with mean postnatal blood lead levels. Significant associations have been demonstrated between umbilical blood lead levels and neurodevelopmental testing at 2 years of age, although the association was not significant at later ages. Blood lead levels at 2 years of age, however, were associated with neurocognitive performance at 10 years of age.¹⁴ A recent analysis of school-aged children demonstrated a stronger cross-sectional inverse association of IQ with contemporary blood lead levels (mean BLL = 8 micro-g/dL at age 7 years) than with baseline blood levels (mean BLL = 26 micro-g/dL at 24 months old), suggesting an ongoing adverse effect of lead on cognitive performance among school-aged children.⁴⁵

Although most cross-sectional studies evaluating the association of tooth and blood lead with IQ display methodological weaknesses such as selection bias and limited adjustment for covariates, they have been generally consistent in reporting small negative effects of elevated lead levels on IQ.^{44, 46} A meta-analysis that included studies of whole tooth lead published since 1979 reported a statistically significant 1-point reduction in IQ associated with a doubling of tooth lead from 5 to 10 micro-g/g.⁴⁴

Cross-sectional studies⁴⁷⁻⁵¹ have consistently reported small, inverse associations between blood or tooth lead and reaction (attentional) performance, but studies evaluating the effect of mildly elevated lead levels on other measures of neurodevelopmental function (e.g., behavior, learning disorders, auditory function) have produced inconclusive results. These have been less thoroughly evaluated than IQ, however, and more recent studies suggest associations between childhood lead exposure and disorders of attention and learning, and aggressive and delinquent behavior.^{14, 35, 52, 53}

In most studies, the size of the estimates of lead effects on IQ are reduced when adjusted for potentially confounding variables,⁴⁴ suggesting that some of the observed association may be due to imperfectly measured or unmeasured covariates. Studies in rodents and primates, however, which can avoid most of the methodological weaknesses of observational studies in humans, report cognitive, attentional, and behavioral deficits, as well as auditory and visual dysfunction, with mildly elevated blood lead levels,⁵⁴⁻⁵⁶ supporting a causal relationship between low-level lead exposure and neurotoxic effects in children.

A growing number of human epidemiology studies have reported associations between neurotoxic effects and blood lead levels once thought to be harmless. Several recent studies have demonstrated an inverse relationship between historical blood lead levels and subsequent measures of intellectual and cognitive performance at blood lead levels of <10 micro-g/dL. The shape of the dose-response curve at levels below 10 micro-g/dL is uncertain although data suggests that lead associated cognitive changes may be greater with incremental changes in blood lead levels in this range.^{14, 35, 53, 57-60} A recent meta-analysis of seven prospective international cohort studies found evidence of deficits on standard IQ testing among children with maximal blood lead levels <7.5 micro-g/dL. A decline of 6.2 IQ points (95% CI, 3.8-8.6) was observed as blood lead levels increased from 1 to 10 micro-g/dL.⁶¹

Lead-associated effects on neurobehavioral functioning must be considered relative to other important covariates such as socioeconomic status, home and parenting environment, and genetic factors.⁵⁷ The contribution of childhood lead exposure to the observed variance in cognitive ability (IQ testing) is believed to be in the range of 1-4%, while social and caregiving factors may be responsible for 40% or more.^{52, 57} Blood lead levels, however, represent a larger proportion of the known, modifiable variance in children's cognitive ability.

Adverse effects of lead exposure on pregnancy outcomes

The effects of very high blood lead levels during pregnancy on reproductive outcomes such as abortion and stillbirth have been recognized for many years.²¹ Observational studies in pregnant women with blood lead levels <30 micro-g/dL have reported associations between elevated levels and birth weight, length of gestation (including preterm delivery), and neonatal head circumference.⁶²⁻⁶⁹ The associations have been small, variable in direction of effect, and not statistically significant in most studies. These studies failed to detect important effects on other reproductive outcomes. Inconsistent results may be due in part to imprecise measures of fetal lead exposure.⁶⁸⁻⁷² All but one⁴² of six previously cited cohort studies,³⁷⁻⁴² as well as the meta-analysis described above,⁴⁴ reported no association between antenatal or perinatal maternal blood lead levels and full-scale IQ measured at preschool or school age. Although very high lead levels in pregnancy are clearly hazardous, the adverse effects on the fetus of antepartum lead levels in the range typically found in the U.S. are not established.

Reproductive effects

A recent review summarizing the epidemiological literature on typical community lead exposure levels, other than those associated with high occupational hazards, states that prenatal lead exposure is unlikely to increase the risk of premature membrane rupture but does appear to

increase the risk of preterm delivery. This review goes on to state that it is unclear whether prenatal lead exposure decreases infant gestational age and that increased exposure appears to be associated with reduced birth weight, but that results vary in relation to study design and degree of control for confounding. Adjustment for gestational age, a possible confounder of the birth weight-lead exposure association, did not yield clearer results.⁷³

The Mexico City Prospective Lead Study examined the association of maternal prenatal blood lead level during pregnancy (range 7.5-9.0 micro-g/dl [0.36-0.43 micro-mol/l]) and child postnatal blood lead level (range of median blood lead level from birth to 48 months 7.0-10.0 micro-g/dl [0.34-0.48 micro-mol/l]) with head circumference, in a sample of Latino immigrants living in Los Angeles. Multiple regression modeling showed significant negative associations ($p < 0.05$, two-tailed) between 6-month head circumference and 36-week maternal blood lead level, and 36-month head circumference and 12-month blood lead level; however, these were the only significant associations among the over fifty assessed in this study.⁷⁴

In 272 mother-infant pairs, tibia bone lead was the only lead biomarker clearly related to birth weight (other significant birth weight predictors included maternal nutritional status, parity, education, gestational age, and smoking during pregnancy). Findings suggest that bone lead might be a better biomarker of lead body burden than blood lead.⁷⁵

Neurodevelopmental and cognitive measures and lead effects

Recent observational studies (prospective cohort and cross-sectional) provide limited, preliminary data that prenatal blood lead levels may be associated with neurodevelopmental delay or impairment. Study design and measurement issues, however, limit interpretation of these studies.

A prospective study of 103 African American neonates with low-level parental lead exposure included a battery of 16 neonatal behavioral assessments at 1 to 2 days after birth. No differences were found in 15 of the 16 domains studied, with neonates in the higher exposure group receiving lower scores on the hand-to-mouth motor activity than did those infants in the lower exposure group ($P < 0.05$).⁷⁶ A sample of 79 African-American infants with low-level prenatal parent lead exposure were given the Fagan Test of Infant Intelligence (FTII) battery at 7 months of age.⁷⁷ Excluding all but infants with scores in the 5th and 95th percentiles of the FTII ($n=5$ in both groups) revealed that subjects rated at high risk for impairment on the FTII (those in the lowest 5th percentile) were 6 times more likely to be in the highest maternal blood lead level quartile ($P < .004$). Infants scoring in the lower 15th percentile ($n=12$), were 2 times more likely to be in the high maternal blood lead level quartile, though significance dropped to $P < 0.056$.⁷⁷ The difference between the mean blood lead levels in the infants with lowest and highest FTII scores (5th and 95th percentiles) was very small, however (0.44 vs. 0.94 micro-g/dL). Recent evidence suggests that children may demonstrate differences in evoked visual and auditory potentials associated with increased levels of prenatal lead exposure.^{78, 79}

Other adverse effects of lead exposure

Lead exposure affects many organ systems, including cardiovascular, renal, and hepatic, but most clinically apparent (i.e., symptomatic) effects occur with blood lead levels ≥ 50 micro-g/dL.^{21, 80-83} Subclinical effects on renal function can be observed at lower levels of exposure and children may be more vulnerable.^{84, 85} Small increases in systolic blood pressure have been associated with mildly elevated blood lead levels (i.e., 1-3 mmHg for a rise in blood lead from 10 to 20 micro-g/dL) in most large, population-based, cross-sectional studies evaluating nonpregnant adults and pregnant women.⁸⁶⁻⁹² In children, evidence of blood pressure effects is more limited: one cross sectional study found no association between elevated blood lead levels (range 7-70 micro-g/dL) and elevated blood pressure.⁹³ Adverse effects on height from lead levels well below 40 micro-g/dL have been suggested by analyses of national cross-sectional data,^{94, 95} but cohort studies with more extensive covariate adjustment report either transient or no effect of elevated lead levels (peak sample means 11-17 micro-g/dL) on growth.^{43, 96, 97}

In a cohort of women in their third trimester, immigrant women were more likely to have elevated blood lead levels and elevated blood pressure, compared to non-immigrant women. An association between elevated blood level and blood pressure was significant only in the immigrant group.⁹⁸ Past lead exposure was associated with hypertension and elevated blood pressure during pregnancy. Bone lead concentration, however, was not shown to be related to hypertension or elevated blood lead in pregnancy.⁹⁹

Among 110 women in their third trimester, gestational hypertension cases showed significantly higher blood lead levels than normotensives, and blood lead was significantly related to blood pressure, even after correcting for body mass indices and age. The lead:ionized calcium ratio showed a stronger association with blood pressure than lead alone.¹⁰⁰ A cross-sectional study of 39 pregnant women in the third trimester of pregnancy compared red blood cell (RBC) levels of lead (Pb) and blood pressure. The study population included 20 women with normal pregnancies, 15 with mild hypertension, and 4 with severe hypertension and preeclampsia. Preeclamptic pregnancies were more likely to have an elevated RBC Pb. Rank correlation showed a significant effect of RBC Pb level on blood pressure.¹⁰¹

Key Question 3: Accuracy of Screening Tests

Can screening tests accurately detect elevated blood lead levels?

Screening tests considered for detecting lead exposure include blood lead and free erythrocyte (or zinc) protoporphyrin levels. Blood lead concentration is the more sensitive of the two for detecting modest lead exposure, but its accuracy, precision and reliability can be affected by environmental lead contamination during blood collection, day-to-day biologic variability, and laboratory analytic variation. Lead contamination of collecting equipment and skin contamination during capillary sampling may each positively bias blood lead levels by up to 1.0 micro-g/dL, on average, although individual effects of skin contamination may be much greater.¹⁰²⁻¹⁰⁶ Studies defining abnormal results as blood lead levels above 10 or 20 micro-g/dL have reported false-positive rates of 3-9% for capillary sampling, compared to simultaneously collected venous blood lead.^{103, 104} Day-to-day biologic variability and trends over time contribute to higher false-positive rates for initial capillary samples when compared to results

from venous testing done at a later date.^{103, 107} False-negative rates with capillary sampling appear to be lower, reported in one study as 1-8% compared to venous blood.¹⁰⁴ In published surveys,^{102, 108} about 80-90% of clinical laboratories participating in proficiency testing programs met performance criteria for blood lead (within +/-4 micro-g/dL of target values, for values <40 micro-g/dL,¹⁰⁸ unpublished national data show >95% of participating laboratories meeting these criteria and >80% achieving accuracy to within +/-2 micro-g/dL of target values (unpublished data, Centers for Disease Control and Prevention, November 1993). Nonparticipating laboratories are likely to be less proficient. Reported blood lead values may differ by as much as 5 micro-g/dL from true values due to these sources of variability and bias, and these divergences may affect the predictive value of a positive test. Results from capillary samples may vary even more, although recent studies suggest that the positive bias can be reduced with increased attention to reducing skin lead contamination.^{103, 104}

The erythrocyte protoporphyrin (EP) test, an indirect measure of lead exposure based on lead's effects on the hematopoietic system, is unaffected by contamination with environmental lead and is easily performed on capillary blood specimens, making it more acceptable for use with young patients. Erythrocyte (or zinc) protoporphyrin is insensitive, however, to modest elevations in blood lead levels.^{8, 109-115} The test also lacks specificity,^{8, 109, 110, 112, 113, 116} thus limiting its predictive value. In one study, EP measurements were taken on 47,230 suburban and rural children, and although 4.7% of the children had an elevated erythrocyte protoporphyrin level, only 0.6% had elevated blood lead levels.¹¹⁷

What is the accuracy of using questionnaires (or other tools) for risk factor assessment at various blood lead levels?

In communities where there is a low prevalence of lead levels requiring individual intervention with chelation or residential lead hazard control, blood lead screening will have a low yield with many unaffected children undergoing testing at potentially high cost and inconvenience. Cross-sectional studies¹¹⁸⁻¹²³ in urban and suburban, mostly Midwestern, populations have shown that one or more positive responses to five questions (about exposures to deteriorated paint from older or renovated housing, to other lead-poisoned children, or to lead-related hobbies or industry)¹²⁴ detects 64-87% of children with blood lead levels ≥ 10 micro-g/dL. Three studies reported higher sensitivities (81-100%) for blood lead levels $\geq 15-20$ micro-g/dL.^{120, 121, 123} None of these studies evaluated the ability of questionnaires to detect levels above 20 micro-g/dL, in part because so few patients had levels so high. Specificity among the studies ranged from 32% to 75%. In the samples with a lower prevalence (2-7%) of levels ≥ 10 micro-g/dL, the proportion of individuals with a negative questionnaire who had elevated blood lead levels was predictably low (0.2-3.5%), but increased to 19% when the population prevalence of elevated lead levels was higher (17-28%).

More recent studies of the utility of questionnaires to assess the risk of lead exposure in children in both urban and rural settings have demonstrated a low prevalence of elevated blood lead levels and poor sensitivity and specificity.¹²⁵⁻¹²⁸ Studies of questionnaires modified for local use provide some evidence of clinical utility for identifying children with elevated blood lead levels,^{128, 129} compared to the standard CDC questionnaire.

Other studies have reported high false-positive rates for questionnaires^{126, 128} and that resource considerations¹²⁵ are important when formulating a screening program. A population-based follow-up study (n=31904) showed that raising the action level for screening to 15 micro-g/dL in this sample would have eliminated the unnecessary follow-up of 5,162 children, 3,360 of whom were falsely identified as having elevated lead levels.¹³⁰

A recent study identified housing risk factors associated with elevated blood lead levels (≥ 10 micro-g/dL) among 481 children residing in Rochester, New York. Housing characteristics including rental status, lead-contaminated floor dust, and poor housing condition were all associated with EBLL (sensitivity 47-92%, specificity 28-76%, positive predictive value 25-34%, negative predictive value 85-93%), suggesting that housing characteristics and floor dust lead levels can be used to identify homes where a lead hazard may exist before or during occupancy.¹³¹

Prenatal screening with questionnaires

A maternal survey using four questions recommended by the CDC was evaluated in a study of 314 new prenatal patients. In this sample, the prevalence of elevated maternal lead levels (at or greater than 10 micrograms/dL or 0.483 mmol/L) was 13%. Subjects with a positive response to at least one question were more likely to have elevated blood lead than those who answered negatively to all four questions (relative risk = 2.39, 95% confidence interval 1.17-4.89; P = .01). The CDC questionnaire had a sensitivity of 75.7%. Among women who answered “no” to all 4 questions, the probability of having an elevated lead level was reduced from 13% to 6.9% (negative predictive value of 93.1%). The most predictive single item was ‘home built before 1960.’ The study also identified a high prevalence of elevated blood lead among children living with women with elevated blood lead levels.⁹

Key Questions 5: Effectiveness of Early Detection

Detection of lead exposure before the development of potentially irreversible complications permits the clinician to recommend environmental interventions to limit further exposure and, when necessary, to begin medical treatment with chelating agents. Early detection may also result in interventions that prevent exposure of other children to lead (the child with elevated blood lead level acting as a sentinel for a hazardous environment). There is relatively little convincing evidence that these interventions improve health, however. One issue is that most available studies in asymptomatic children evaluate the effects of various interventions on blood lead levels rather than on clinical outcomes. Second, blood lead levels in childhood, after peaking at about 2 years of age, decrease even without intervention.⁶ Longitudinal studies of asymptomatic children with elevated lead levels show reductions in blood lead levels during short- and long-term follow-up in the absence of any intervention,^{132, 133} a result attributable at least in part to regression to the mean, random variation, laboratory error, and redistribution from blood to other tissues. To evaluate adequately the effects of interventions on blood lead levels, studies must take into account these changes over time, preferably by the use of controls, individuals who do not receive the intervention.

Effect of screening on clinical outcomes

Evidence is not available to demonstrate that universal screening for blood lead results in better clinical outcomes than either screening targeted to high-risk persons or individualized testing in response to clinical suspicion. Several older studies reported that, compared to historical results from individualized testing, intensive screening programs targeted to children in high-risk neighborhoods reduced case fatality rates, mortality rates, and proportions of children detected with very high blood lead levels or who developed symptomatic lead poisoning.¹³⁴⁻¹³⁶ In the absence of concurrent controls, it is not clear whether the reported reductions in mortality and case fatality rates were due to screening or to improvements in medical care over time. Reductions in mean lead levels may also have been due to secular trends, changes in screening tests, and to screening greater numbers of children, including many at low risk for severe lead poisoning. Thus, the available evidence regarding the efficacy of screening programs is weak.

Do interventions for elevated lead levels result in improved health outcomes?

There is substantial evidence that chelating agents benefit children with symptomatic lead poisoning, but no studies have demonstrated clinical benefits of chelation therapy in asymptomatic children. A large multicenter randomized controlled trial sponsored by the U.S. National Institute for Environmental Health Science (NIEHS) enrolled children in 1994-1997 to assess the effect of oral chelation therapy with succimer on IQ in young children with venous blood lead concentrations of 20-45 micro-g/dL.¹³⁷ Follow-up testing at 36 months demonstrated a mean IQ one point lower and a lower parental rating of behavior among the succimer group compared to placebo. Although succimer-treated children did slightly better on a test of learning ability, none of the differences between the groups were statistically significant.¹³⁸ Reanalysis of the same data using the change in blood lead level as the independent variable demonstrated a 4.0 point improvement in cognitive scores for every 10 micro-g/dL reduction in blood lead level, but only in the placebo group, suggesting that factors other than declining blood lead contributed to cognitive improvement, or that treatment had an adverse effect on cognitive performance.¹³⁹ Assessment of neurobehavioral outcomes at 7 years of age revealed no statistically significant differences on a battery of neurobehavioral tests, except that the succimer group had worse attention-executive function scores.¹⁴⁰ Treatment also appeared to have an adverse effect on mean height.¹⁴¹ The Trial Group concluded that chelation therapy was not indicated for children with blood lead levels <45 micro-g/dL.^{138, 140}

An observational study^{142, 143} compared children with blood lead levels between 13 and 46 micro-g/dL (median 30 micro-g/dL), who did and did not receive EDTA chelation therapy depending on the results of a lead mobilization test. There was no effect of chelation on IQ at either 7 weeks or 6 months follow-up after controlling for age and initial IQ. Changes in concentrations of blood lead, bone lead, and EP also did not differ significantly between chelated and unchelated children. The greatest reductions in blood lead were associated with the highest initial lead levels, independent of chelation. The method of treatment assignment (i.e., based on a positive mobilization test) was most likely to have biased the study toward finding an effect of chelation, yet no effect was observed. Despite evidence of efficacy in lowering blood lead on a short term basis, there is little evidence presently available to confirm a clinical benefit from chelation

therapy for children with lead levels <45 micro-g/dL. Ethical considerations preclude such trials for children with blood lead levels above 45 micro-g/dL.

We found no studies evaluating clinical outcomes after residential lead hazard control.

Effects of chelation therapy on blood lead levels

In the previously cited NIEHS-sponsored RCT of oral chelation in young children with venous blood lead concentrations of 20-45 micro-g/dL (TLC Study), which reported no effects of chelation on IQ (Table 1),^{137-140, 144} blood lead levels fell steeply in the treatment group in the first week (mean 11 micro-g/dL lower) but then began to rebound. Blood lead levels also dropped in the placebo group, but more slowly. Blood lead levels were 77% of baseline in the succimer group (88% of baseline among placebo) at seven weeks after initiation of therapy. Mean blood lead levels among the treatment group were 4.5 micro-g/dL and 2.7 micro-g/dL, at six and twelve months respectively, but by 24 months the difference between treatment and placebo groups was not significant.¹⁴⁴

Chelating agents have demonstrated short-term reductions in blood lead levels in children whose pretreatment values ranged from 20 to 70 micro-g/dL in randomized comparative trials, case series studies, and uncontrolled experiments where chelation therapy was often combined with environmental interventions, but these reductions were not sustained over longer periods in the absence of repeated or continuing chelation therapy or environmental interventions.¹⁴⁵⁻¹⁵²

In other descriptive studies (case series, uncontrolled trials, etc.) of asymptomatic children with initial blood lead levels ranging from 40 to 471 micro-g/dL, chelating agents reduced blood lead levels substantially, to levels <40-70 micro-g/dL (varying with initial levels) and these reductions were maintained for weeks to years after therapy was discontinued (Table 1).^{145, 153-157} Most of these children were also returned to homes that had undergone lead hazard reduction, however, and the effect of this additional intervention was not specifically evaluated.

These data provide good evidence that chelating agents may result in short-term reductions in blood lead levels in children but suggest that these reductions may not be sustained over longer periods in the absence of repeated or continuing chelation therapy or environmental interventions.

Effect of residential lead hazard control on blood lead levels

Summary: Recent studies of household dust and paint hazard control through cleaning, abatement and education have mixed results. Of the eight controlled studies published since 1995, one has shown a modest but significant decline, five have shown non-significant declines, and two have shown non-significant elevations in blood lead levels among children. Reduced blood lead levels were seen among children with higher baseline lead levels (15+ or 20+ micro-g/dL) in 2 studies (1 meta-analysis, 1 retrospective chart review with no comparison group), but not in children with lower baseline levels. Recent studies differ from older studies in that newer paint hazard control techniques result in lower dust lead levels. Population venous lead-levels

have decreased over time, and lead-poisoned children in older studies had higher mean Blood lead levels than in recent studies.

Detailed assessment: (Tables 2 and 3) For most asymptomatic children with elevated lead levels, the primary goal of intervention is to reduce exposure to lead-contaminated paint, dust, and soil in the child's home environment, since these sources account for most excess lead exposure. Newer residential lead-based paint hazard control methods can effectively reduce environmental exposure to lead paint and lead-contaminated dust^{23, 158, 159} in contrast to older strategies that often increased lead exposure during the intervention. These newer techniques, however, can result in an elevation of blood lead in a subset of children immediately following lead control interventions. In an evaluation of HUD-sponsored lead control interventions among fourteen state and local governments, 81 of 869 children (9.3%) had an elevation of ≥ 5 micro-g/dL. Risk factors associated with post-intervention increases were the number of exterior paint deteriorations, the educational level of the female parent or caregiver and the younger age of the child.¹⁶⁰

Pre-1996 retrospective cohort studies, case series, and uncontrolled experiments suggest that there is a modest decline (4-10 micro-g/dL) in mean blood lead levels in children with initial blood lead levels ≥ 25 micro-g/dL. More recent studies of newer lead-based paint hazard control techniques that included an untreated comparison group found small beneficial effects^{161, 162} or no effects of intervention.^{163, 164}

A meta-analysis of 4 randomized controlled trials conducted between 1996 and 2000, found that interventions had no effect on mean blood levels (-0.62 micro-g/dL, 95% CI -1.55 to 0.32), but that there were significant reductions in the proportion of children who had blood lead concentrations exceeding 15 micro-g/dL (6% vs. 14%, $p=0.008$) and 20 micro-g/dL (2% vs. 6%, $p=0.024$) in the intervention group compared with the controls.¹⁶⁵

Two of these 4 trials evaluated dust control and two evaluated the provision of education and equipment to families. The earlier of the two trials of dust control (1998) evaluated one-time professional dust control and window sill paint sealing in homes of children aged 4 or younger, with mean blood lead of 16.9 micro-g/dL.¹⁶³ There were similar reductions in blood levels in the intervention and control groups (-6.2 vs. -5.9 micro-g/dL) 6 months after abatement. In the 2nd randomized trial (1999), conducted in Jersey City, New Jersey, investigators recruited children aged 6 to 36 months who had lead paint in the home. Families ($n=113$) were randomized to a lead exposure reduction group or to an accident prevention control group. In the lead exposure reduction group, staff members visited the home every two weeks and spent about 2 hours cleaning up dust. After 1 year, there was a small but statistically significant difference in blood lead change between intervention and control groups, adjusted for baseline lead levels (-2.1 vs. +0.1 micro-g/dL, $p<0.05$).¹⁶¹ A subanalysis of this trial found that among 39 homes that received the intervention, only children in uncarpeted homes experienced a significant reduction in blood lead levels. Mean blood lead level decreased by 2.76 micro-g/dL ($p=0.004$) among children in uncarpeted homes, compared with a reduction of 0.84 micro-g/dL ($p=ns$) among children in carpeted homes.¹⁶⁶

A follow-up study in urban children in a trial of chelation therapy vs. placebo examined the effects of a second professional lead dust cleaning of homes 18 months after an initial cleaning and commencement of therapy.¹⁶⁷ All homes in the Philadelphia site (n=165) of the TLC trial¹⁴⁴ were offered a second professional cleaning, and subject participation in the follow-up intervention was voluntary rather than randomized. The mean BLL at study initiation was 26 micro-g/dL, and the randomized trial found no difference in blood lead levels between the chelation and placebo groups. The mean BLL was 15.7 micro-g/dL at the second cleaning visit, and 6 months later there was no difference in blood lead levels between children whose homes were cleaned (n=73) and those whose homes were not cleaned (n=86). The report of the follow-up cleaning trial did not stratify results by the original treatment assignment of the subjects, so the effects of the combined interventions cannot be compared with an untreated group.

A 2003 retrospective cohort study identified children listed in the New York City child blood lead registry and compared blood levels before and 10-14 months after remediation with those of a control group that did not have remediation.¹⁶⁴ Mean blood levels declined significantly from 24.3 micro-g/dL to 12.3 micro-g/dL at follow up, regardless of remediation. After adjusting for confounders, the remediation effect was 11% (p=ns). Race was identified as the only confounding factor, and white and Asian children had an adjusted mean follow-up blood lead level 30% lower than African American children (p<0.01). The effect of remediation appeared to be stronger in younger children (10 -<36 months) than in older children (36-72 months.) Another retrospective cohort study that evaluated in-home counseling, combined with professional lead paint remediation, compared lead levels in children aged 6 months to 6 years with mean blood lead of 28.8 micro-g/dL with similar children who did not receive the intervention.¹⁶² Follow-up blood lead was measured on average 69 days after abatement, 172 days after the initial sample. After adjusting for season and age of the child, the treatment group blood lead decreased 6.0 micro-g/dL from 28.8 to 22.8, and the effect of treatment was significant (p<0.05). The comparison group mean blood lead decreased 1.6 micro-g/dL from 31.1 to 29.5 (p=ns).

In a retrospective study that measured blood lead levels in children whose homes were abated between 1987 and 1990, before and after abatement policies in Massachusetts became more stringent in 1988, the mean blood lead decreased from 26.0 micro-g/dL at baseline to 21.2 micro-g/dL (p<0.001) measured between 2 weeks to 6 months post abatement. Reductions were only seen, however, among children whose baseline blood lead levels were greater than 20 micro-g/dL. This study found no meaningful change in pre to post abatement levels by calendar year of intervention.¹⁶⁸ The effect of different housing policies on the risk of subsequent lead exposure in homes where a child with elevated blood lead had resided in the past was demonstrated in adjacent geographic regions of two northeastern states. Approximately eight years later, the risk of identifying at least one child with an elevated blood lead level (≥ 10 micro-g/dL) was four times greater in the state with less stringent housing-based lead poisoning prevention policies.¹⁶⁹

A study of 1212 HUD dwellings that received interior treatment for lead hazard control in thirteen states from 1994 to 1998 reported a mean 2.8 micro-g/dL reduction in children's (n=240) blood lead levels at 12 months postintervention, from a median level of 10 micro-g/dL at baseline.¹⁷⁰ The effect of treatment in these studies was not compared with an untreated population. Another study of HUD dwellings in four Massachusetts communities found a

significantly larger decline in blood lead levels between 1993 and 2002 among children in treated homes than in untreated homes, matching on preintervention BLL. Children's BLLs decreased from 7.07 and 6.62 micro-g/dL to 3.59 and 4.28 in the treated and untreated homes respectively (p=0.015). The study adjusted for time and seasonality to account for the downward trend in BLLs observed among children in the general Massachusetts population, from 5.9 micro-g/dL in 1994 to 3.2 ug/dL in 2002.¹⁷¹

These trials also highlight important problems with using lead-paint hazard control as the sole method to reduce lead exposure. Poor inner-city families tend to move frequently, so that treating the current residence may have limited long-term benefit to the child, although benefit may accrue to other children moving into that residence. In the Jersey City study, for example, approximately 30% of the randomized families moved during the 12-month follow-up period.¹⁶¹ Residential lead-paint hazard control is costly and labor-intensive, resulting in low rates of intervention, especially in poor communities.^{22, 172} Lead dust is ubiquitous and highly mobile, so that recontamination by nearby lead sources, including soil lead, may occur after lead-paint hazard control efforts take place in a dwelling.^{158, 173-175} These problems indicate a need for additional individual interventions, as well as more comprehensive community-based interventions, to reduce household lead exposure. Unfortunately, available data about programs that employ multiple interventions are sparse.^{157, 160}

The small effect noted in studies evaluating lead-paint hazard control methods may be attributable in part to recontamination of the dwelling by nearby lead sources and from subsequent deterioration of painted surfaces.^{158, 173, 174} Several studies have evaluated measures designed to reduce ongoing lead-dust contamination from lead-contaminated paint and soil. In a nonrandomized controlled trial among children with blood lead levels of 30-49 micro-g/dL, having a research team wet-mop all lead-contaminated interior surfaces twice a month with a high-phosphate detergent cleanser resulted in significantly greater adjusted declines in mean blood lead levels of children in intervention households compared to children in control households (6.9 vs. 0.7 micro-g/dL) at 1-year follow-up.¹⁷⁶

Counseling and education interventions

Summary: Overall, there is insufficient evidence to determine whether education and counseling improves outcomes among children with moderately elevated blood lead levels. Blood lead reductions of varying magnitude occurred in children whose families received no intervention.

Detailed assessment: There have been no controlled studies to evaluate whether counseling families to perform cleaning would be as effective in reducing blood lead levels as professional cleaning. Two randomized controlled trials that administered counseling alone,¹⁷⁷ or with the provision of cleaning supplies,¹⁷⁸ found no significant effects of the intervention on children's blood lead levels. A retrospective cohort study of children with blood lead of 20-24 micro-g/dL found that a one-time in-home educational visit was associated with a greater reduction in blood lead after 6 months, compared with households that did not receive an educational visit (-4.2 micro-g/dL vs. -1.2 micro-g/dL, p<0.001).¹⁷⁹ In one uncontrolled experiment, the families of 78 children with blood lead levels of 10-35 micro-g/dL, who were living in the vicinity of a defunct

lead smelter, received intensive (30-45 minutes) in-home education and literature on prevention of lead exposure.¹⁸⁰ The mean blood lead levels in the 51 (65%) children who had follow-up blood lead levels at 4 months declined from 15.0 to 7.8 micro-g/dL (and maximum levels from 35.0 to 12.7 micro-g/dL). Without concurrent controls, it is not possible to determine how much regression to the mean and seasonal and age variations contributed to these reductions in blood lead levels. There is also evidence that clinician counseling at the worksite to reduce lead dust ingestion by workers (e.g., through personal hygiene practices) can significantly reduce mean blood lead levels at 1-year follow-up,¹⁸¹ but this study also lacked controls and may not be generalizable to the residential setting.

Soil abatement

Summary: Recent studies of soil remediation in residential areas have shown only modest or non-significant effects.^{175, 182, 183} Soil remediation in communities near lead mining, milling, or smelting operations may have a beneficial effect but was not considered within the scope of review.

A third focus of residential lead hazard control is exposure to soil lead. In a randomized controlled trial¹⁷³ of young children with initial blood lead levels of 7-24 micro-g/dL, extensive soil abatement, one-time dust abatement, and removal of loose interior paint resulted in a statistically significant reduction in mean blood lead levels of 1.2-1.3 micro-g/dL compared to loose paint removal alone. This clinically insignificant decline was associated with a substantial reduction in soil lead from a median 2,000 to 105 ppm. Preliminary results of the U.S. Environmental Protection Agency's Three City Urban Soil Lead Abatement Demonstration Project similarly suggest that substantial declines in soil lead cause only modest or no reduction in mildly elevated blood lead concentrations.^{174, 175, 182, 183} The small effect was due at least in part to rapid recontamination with dust lead in households undergoing soil abatement. Among children living near a closed lead smelter, only 3% of the variance in blood lead levels was attributable to soil lead.¹⁸⁰

An important potential public health benefit of residential lead hazard control is its effect on the lead levels or clinical outcomes of other children who live in the same household as a child identified with elevated lead levels, or who subsequently move into the remediated residence. Based on the biokinetics of lead,²¹ it is reasonable to believe that environmental interventions conducted before children are exposed are likely to prevent increases in blood lead levels more effectively than the same interventions in children who have already been exposed. Cross-sectional surveys before and after soil abatement in the vicinity of a former smelting and milling operation observed a statistically significant reduction in blood lead levels among children aged 6-36 months who had not been exposed to lead-contaminated yards in early childhood. A significant reduction was not seen in children aged 36-72 months.¹⁸⁴

Effect of nutritional interventions on blood lead levels

Summary: There is insufficient evidence to determine whether nutritional interventions are an efficacious route to lowering children's blood lead levels.

Detailed assessment: In most settings, neither residential lead-based paint nor dust hazard control nor chelation therapy is routinely offered to children with blood lead levels <20 microg/dL, but some experts have recommended offering these children dietary counseling to reduce their blood lead levels.¹²⁴ There is limited, preliminary, and somewhat contradictory evidence that correcting such nutritional inadequacies will reduce blood lead levels or prevent further increases in children, depending on the nutritional intervention under investigation (Tables 4 and 5).^{157, 185-194}

Three RCTs^{185, 189, 190} and three prospective cohort studies^{191, 192, 195} did not find a significant correlation between calcium and blood lead levels, although one prospective cohort study¹⁹⁶ found an inverse association. Fat and caloric intakes were positively associated with blood levels in a prospective cohort study¹⁸⁶ and a cross-sectional study.¹⁸⁸ Carbohydrates had an inverse association according to a prospective cohort study.¹⁸⁶ Two prospective cohort studies^{191, 192} found that ferritin is not significantly related to blood lead levels. One cross-sectional study¹² found a positive association with folate and a negative association with serum folate. Iron has not been shown to have an effect on blood lead levels in two RCTs^{185, 190} and one prospective cohort study,¹⁵⁷ although three prospective cohort studies^{191, 192, 195} and one cross-sectional study¹⁸⁷ reveal a negative association, while one cross-sectional study shows a positive association.¹² Two RCTs^{185, 190} found no correlation between blood lead levels and phosphorus. One cross-sectional study found a positive association between blood lead levels and pyridoxine.¹² Protein had a paradoxical effect in one prospective cohort study, significantly associating with low lead levels at 6 months, but then higher lead levels at 12 months.¹⁹¹ Two prospective cohort studies showed no relationship between supplement use and blood lead levels.^{191, 192} One cross-sectional study found a negative association between blood lead levels and thiamine.¹² Vitamin C is inversely related with blood lead levels according to a prospective cohort study.¹⁸⁶ Vitamin C has also been inversely associated with blood lead levels in a cross-sectional study,¹⁹³ Dietary vitamin D is also inversely related to blood lead levels according to a prospective cohort study,¹⁹² whereas serum vitamin D has not been correlated with blood lead levels in two prospective cohort studies.^{191, 192} Two prospective cohort studies yielded different results concerning zinc, showing no association to blood lead levels,¹⁹¹ and conflicting results.¹⁹²

Despite the significant relationships between nutrients and children's blood lead levels in the epidemiological studies described above, it is noticeable that none of the RCTs found significant correlations.^{185, 189, 190} Similarly, a 2004 retrospective cohort study, using data from the Wisconsin Childhood Lead Poisoning Prevention Program in children aged 0-6, compared blood levels of children enrolled in the Special Supplemental Nutrition Program for Women, Infants, and Children from 1996 to 2000 with blood levels of children not enrolled in the nutrition program, and did not find any significant differences between the two groups.¹⁹⁴ Other cohort studies reveal significant association with calories, carbohydrates, fat, iron, vitamin C and vitamin D,^{157, 186, 191, 192, 195, 196} whereas the cross-sectional studies demonstrate significant associations with ascorbic acid, calories, fat, folate, serum folate, iron, pyridoxine, and thiamine.^{12, 187, 188, 193} Adverse effects were reported in two of the fourteen studies; both are RCTs. A calcium study using a 1800 mg/d¹⁸⁹ dosage reported abdominal pain in both the treatment and control groups. A calcium glycerophosphate-supplemented infant formula study reported elevated ratios of urinary calcium to creatinine and low concentrations of serum ferritin,

but these effects also occurred in both the treatment and placebo groups.¹⁹⁰ None of the other studies reported adverse effects.

A recent review concluded that experimental studies in animals and observational studies of humans provide evidence that calcium supplementation during the second half of pregnancy may reduce prenatal lead exposure by reducing mobilization of lead from bone.¹⁹⁷

Key Questions 4 and 6: Adverse Effects of Screening and Intervention

The most common adverse effects of screening for elevated lead levels are false-positive fingerstick results, and the anxiety, inconvenience, work or school absenteeism, and financial costs associated with return visits and repeat tests. An EDTA lead mobilization test, used for some children with blood lead levels of 30-44 micro-g/dL,¹⁹⁸ requires intramuscular or intravenous infusion, a stay at the clinical center for at least 8 hours, and for young children, application of urine collection bags.¹⁹⁹ Residential lead-based paint and dust hazard control, when improperly done,²³ may produce acute increases in blood lead levels in resident children and abatement workers, occasionally necessitating hospitalization and chelation therapy.²⁰⁰⁻²⁰⁴ Currently recommended techniques for lead hazard reduction are likely to reduce these adverse effects.²³ Chelating agents for asymptomatic lead poisoning have also been associated with important adverse effects. EDTA and dimercaprol (BAL) have transient renal, hepatic, and other toxicity, require intravenous or intramuscular injection, and generally require hospitalization for administration.^{124, 205, 206} Common adverse effects of d-penicillamine are penicillin-like sensitivity reactions and transient nephrotoxicity which may be dose-related²⁰⁷; there are rare life-threatening reactions.^{124, 134, 147, 156} Adverse effects of succimer (meso-2,3-dimercaptosuccinic acid, or DMSA) include mild gastrointestinal (vomiting and diarrhea) and systemic symptoms, rashes, transient hyperphosphatasemia, neutropenia, eosinophilia and elevations in serum transaminases, in up to 10% of cases.^{137-140, 144-146, 148, 208}

RECOMMENDATIONS OF OTHER GROUPS

The CDC updated its lead screening recommendations in 1997 in response to evidence of inadequate screening of children at high risk, and to concerns regarding appropriate use of limited resources in low prevalence communities. The revised CDC guidelines provided state public health entities with authority and guidance to develop state and local policies for childhood lead screening. The CDC recommended universal screening in communities without data regarding the prevalence of elevated blood lead levels adequate for local policy development, and in communities where $\geq 27\%$ of the housing was built before 1950. Screening of all children receiving Medicaid, Supplemental Food Program for Women, Infants and Children (WIC) or other governmental assistance, and in populations where $\geq 12\%$ of children ages 1-2 years have elevated blood lead levels was also recommended. Targeted screening is recommended for all other children based on individual risk assessment.²⁷ This approach is also supported by the American College of Preventive Medicine.²⁰⁹

The American Academy of Pediatrics recommends that pediatricians:

- (1) Provide anticipatory guidance to parents of all infants and children regarding potential risk factors and specific prevention strategies tailored for the family and community.
- (2) In conjunction with public health authorities, develop and use community-specific risk assessment questionnaires to guide targeted screening in communities where universal screening is not appropriate.
- (3) Provide lead screening at age 9-12 months and consider again at ~24 months following state health department guidelines utilizing individualized targeted or universal screening as recommended.
- (4) Assess possible lead exposure periodically between 6 months and 6 years of age using community-specific risk assessment questionnaires. Blood lead testing should be considered in children with a history of abuse, neglect, or conditions associated with increased lead exposure.
- (5) Actively participate in state and local lead poisoning prevention activities.

Recommendations by the AAP regarding the urgency and extent of follow-up differ slightly from those of the CDC, and depend on the risk classification and on confirmed venous blood lead levels.²¹⁰

The American Academy of Family Physicians (AAFP) recommends lead screening at 12 months of age in infants who have the following risk factors:

- residence in a community with a high or undefined prevalence of lead levels requiring intervention,
- residence in or frequent visits to a home built before 1950 that has dilapidated paint or has recently undergone or is undergoing renovation or remodeling,
- close contact to a person who has an elevated blood lead level,
- residence near a lead industry or heavy traffic,
- residence with a person whose hobby or job involves lead exposure,
- use of lead-based pottery,
- or use of traditional remedies that contain lead.²¹¹

Medicaid's Early and Periodic Screening, Diagnostic, and Treatment Program requires that all children be considered at risk and must be screened for lead poisoning. CMS requires that all children receive a screening blood lead test at 12 months and 24 months of age. Children between the ages of 36 months and 72 months of age must receive a screening blood lead test if they have not been previously screened for lead poisoning. At this time states may not adopt a statewide plan for screening children for lead poisoning that does not require lead screening for all Medicaid-eligible children.^{5, 212}

Studies of provider behavior before and after the 1997 Revision of the CDC Recommendations demonstrate that blood lead screening and follow-up of children is often inadequate.^{213, 214}

Recently, the CDC Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP) reaffirmed its support for state and local decision making based on local data and conditions regarding the appropriate lead screening recommendations. The ACCLPP also acknowledged the

limitations of screening and other forms of secondary prevention, and advocated a increased local and national focus on housing-based primary prevention of lead exposure.²⁹

No national organizations currently recommend screening pregnant women for elevated lead levels. Some state organizations have developed local policies regarding lead screening. In 1995, the New York State Department of Health and American College of Obstetricians and Gynecologists District II developed lead poisoning prevention guidelines that mandate anticipatory guidance for pregnant women, risk assessment, and risk reduction counseling and childhood lead poisoning prevention education.²¹⁵

DISCUSSION

A summary of the evidence for each key question addressed in the evidence synthesis is provided in Table 6. There is fair evidence that screening for elevated lead levels in asymptomatic children at increased risk for lead exposure will improve clinical outcomes. Because there have been no controlled trials directly evaluating screening for elevated lead levels, this conclusion is based on a chain of evidence constructed from studies of weaker design. First, in young asymptomatic children, blood lead levels as low as 10 micro-g/dL and perhaps lower are associated with measurable neurodevelopmental dysfunction. Second, although the national prevalence of elevated lead levels has declined substantially in the past two decades, a high prevalence persists in some communities, particularly poor urban communities in the Northeast and Midwest U.S. Third, measurement of venous blood lead concentration is a reliable, precise and reasonably valid screening test for assessing lead exposure. Fourth, current interventions, including residential lead hazard control and chelation therapy, can reduce blood lead levels in children identified with levels ≥ 25 micro-g/dL, although the quality of evidence supporting their effectiveness is weak and a beneficial effect on IQ or other clinical outcomes has not yet been demonstrated. Well-designed randomized controlled trials do not support beneficial effects of chelation therapy for asymptomatic children with levels < 45 micro-g/dL. There is also weak evidence that screening high-risk children for elevated lead levels results in improved clinical outcome compared to historical controls identified by case finding. Based on this evidence of the current burden of suffering and the effectiveness of early detection, the Task Force recommends screening children at increased risk for lead exposure.

While no studies have evaluated a specific age at which to screen, the natural history of blood lead levels in children, which increase most rapidly between 6 and 12 months and peak at age 18-24 months, suggests that screening at about 12 months of age is likely to be most effective for the early detection of elevated lead levels.

For those children who are screened and found to have initial blood lead levels < 25 micro-g/dL, there is as yet little evidence regarding the effectiveness of early detection and intervention, or of repeated screening to detect further increases in blood lead. Longitudinal and cross-sectional studies suggest that in children ≥ 2 years, most such levels will decline naturally with time, but elevated levels may persist in children who are chronically exposed.

There is no direct evidence comparing the outcomes of universal screening with the outcomes from targeted screening for elevated lead levels. Recent studies indicate that the prevalence of elevated blood levels in the U.S. has declined dramatically in the past two decades, but local prevalence is highly variable, with more than tenfold differences between communities. In a community with a low prevalence of elevated blood lead levels, universal screening may result in disproportionate risks and costs relative to benefits. The prevalence level at which targeted screening can replace universal screening is a public health policy decision requiring consideration of factors in addition to the scientific evidence for effectiveness of early detection, such as available resources, competing public health needs, and costs and availability of alternative approaches to reducing lead exposure. Clinicians can consult with their local or state health department regarding appropriate screening policy for the local child population.

In communities where data suggest that universal screening is not indicated, there may nevertheless be some children who are at increased risk of blood lead levels in the range for which individual intervention by chelation therapy or residential lead hazard control has been demonstrated to be effective. In addition to risks from housing, these children may have had exposure to other lead sources such as lead-based hobbies or industries, traditional ethnic remedies, or lead-based pottery. Selective blood lead screening of such high-risk children is appropriate even in low prevalence communities. There is fair evidence that a validated questionnaire of known and acceptable sensitivity and specificity can identify those at high risk. In several studies, the CDC¹²⁴ and similar questionnaires correctly identified 64% to 87% of urban and suburban children who had blood lead levels ≥ 10 micro-g/dL. These questionnaires have not been adequately evaluated as a screening tool to detect higher blood lead levels (e.g., ≥ 20 -25 micro-g/dL), or to detect exposure in other populations (e.g., migrant workers, rural communities). Locale-specific questionnaires that inquire about likely local sources of lead exposure may lead to improved prediction.

As is the case in children, there are no controlled trials evaluating screening for elevated lead levels in pregnant women, nor are there sufficient data to construct an adequate chain of evidence demonstrating benefit. The prevalence of levels >15 micro-g/dL appears to be quite low in pregnant women. There is fair evidence that mildly elevated lead levels during pregnancy are associated with small increases in antepartum blood pressure, but limited evidence that these levels have important adverse effects on reproductive or other outcomes, including intelligence of offspring. An extensive literature search failed to identify studies evaluating screening or intervention for lead exposure in pregnant women. There are potentially important adverse effects of chelation therapy on the fetus and of residential lead hazard control on both the pregnant woman and fetus if they are not performed according to established standards. Removal to a lead-free environment would theoretically be effective in reducing lead exposure but has not been specifically evaluated in pregnancy. There is thus insufficient evidence to recommend for or against screening pregnant women for the detection of elevated lead levels.

Community-based interventions for the primary prevention of lead exposure are likely to be more effective, and may be more cost-effective, than office-based screening, treatment and counseling.²⁹ Community, regional, and national environmental lead hazard reduction efforts, such as reducing lead in industrial emissions, gasoline, and cans, have proven highly effective in reducing population blood lead levels.²¹⁶⁻²²³ Remaining important sources of lead (e.g., lead paint

and pipes in older homes, lead-contaminated soil) are, however, more difficult to address on a population-wide basis. Studies of community-based efforts to reduce lead exposure from these and other sources in order to prevent the occurrence of elevated lead levels are ongoing.^{23, 158, 224} Evaluation of the effectiveness of community-based interventions, and recommendations regarding their use, are beyond the scope of this document.

REFERENCES

1. DiGuseppi C. Screening for Elevated Lead Levels in Childhood and Pregnancy. *Guide to Clinical Preventive Services: Report of the U. S. Preventive Services Task Force*. 2nd ed. Baltimore: Williams & Wilkins; 1996.
2. U. S. Preventive Services Task Force. Screening for Elevated Lead Levels in Childhood and Pregnancy: Recommendation. *Guide to Clinical Preventive Services: Report of the U. S. Preventive Services Task Force*. 2nd ed. Baltimore: Williams & Wilkins; 1996.
3. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force. A review of the process. *Am J Prev Med*. 2001;30(3S):21-35.
4. Bellinger DC, Hu H, Kalaniti K, et al. A pilot study of blood lead levels and neurobehavioral function in children living in Chennai, India. *Int J Occup Environ Health*. 2005;11(2):138-143.
5. Centers for Disease Control and Prevention. Blood Lead Levels - United States, 1999-2002. *MMWR*. 2005;54(20):513-516.
6. Brody DJ, Pirkle JL, Kramer RA, et al. Blood lead levels in the US population. Phase 1 of the Third National Health and Nutrition Examination Survey (NHANES III, 1988 to 1991) [erratum appears in JAMA 1995 Jul 12;274(2):130]. *JAMA*. 1994;272(4):277-283.
7. Fredeen DJ, Ehlinger EP, Cruikshank SH, Godes JR, Braun JE, Deinard AS. Lead levels among pregnant women in Hennepin County. *Minnesota Medicine*. 1992;75(11):29-32.
8. Flanigan GD, Jr., Mayfield R, Blumenthal HT. Studies on lead exposure in patients of a neighborhood health center: Part II. A comparison of women of childbearing age and children. *J Nat Med Assoc*. 1992;84(1):23-27.
9. Stefanak MA, Bourguet CC, Benzies-Styka T. Use of the Centers for Disease Control and Prevention childhood lead poisoning risk questionnaire to predict blood lead elevations in pregnant women. *Obstet Gynecol*. 1996;87(2):209-212.
10. Crocetti AF, Mushak P, Schwartz J. Determination of numbers of lead-exposed women of childbearing age and pregnant women: An integrated summary of a report to the U.S. Congress on childhood lead poisoning. *Environ Health Perspect*. 1990;89:121-124.
11. Rhainds M, Levallois P, Dewailly E, Ayotte P. Lead, mercury, and organochlorine compound levels in cord blood in Quebec, Canada. *Arch Environ Health*. 1999;54(1):40-47.
12. Lee MG, Chun OK, Song WO. Determinants of the blood lead level of US women of reproductive age. *J Am Coll Nutr*. 2005;24(1):1-9.
13. Hu H, Hashimoto D, Besser M. Levels of lead in blood and bone of women giving birth in a Boston hospital. *Arch Environ Health*. 1996;51(1):52-58.
14. Needleman H. Lead poisoning. *Annu Rev Med*. 2004;55:209-222.
15. Centers for Disease Control and Prevention. Elevated blood lead levels in refugee children: New Hampshire, 2003-2004. *MMWR*. 2005;54(2):42-46.
16. centers for Disease Control and Prevention. CDC Recommendations for Lead Poisoning Prevention in Newly Arrived Refugee Children. Added 6.8.05; www.cdc.gov/nceh/lead/refugee%20recs.htm. Accessed June 2, 2005, 2005.
17. Surveillance for elevated blood lead levels among children: United States, 1997-2001. *MMWR*. 2003;52(SS10):1-21.

18. From the Centers for Disease Control and Prevention. Blood lead levels in young children--United States and selected states, 1996-1999. *JAMA*. 2001;285(3):286-287.
19. Children with elevated blood lead levels attributed to home renovation and remodeling activities--New York, 1993-1994. *MMWR*. 1997;45(51-52):1120-1123.
20. Sargent JD, Brown MJ, Freeman JL, Bailey A, Goodman D, Freeman DH, Jr. Childhood lead poisoning in Massachusetts communities: its association with sociodemographic and housing characteristics. *Am J Public Health*. 1995;85(4):528-534.
21. Committee on Measuring Lead in Critical Populations NRC. Measuring lead exposure in infants, children, and other sensitive populations. *Washington DC: National Academy Press*. 1993.
22. Agency for Toxic Substances and Disease Registry. The nature and extent of lead poisoning in children in the United States: a report to Congress. *Atlanta: Department of Health and Human Services*. 1988;Publication no. DHHS-99-2966.
23. Department of Housing and Urban Development. Comprehensive and workable plan for the abatement of lead-based paint in privately owned housing. *Report to Congress. Washington, DC*. 1990;Publication no. HUD-PDR-1295.
24. Environmental Protection Agency. Reducing lead in drinking water: a benefit analysis. *Washington, DC: Environmental Protection Agency*. 1986;Office of Policy Planning and Evaluation.
25. Arnetz BB, Nicolich MJ. Modeling of environmental lead contributors to blood lead in human. *Int Arch Occup Environ Health*. 1990;62(5):397-402.
26. Jacobs DE, Clickner RP, Zhou JY, et al. The prevalence of lead-based paint hazards in U.S. housing. *Environ Health Perspect*. 2002;110(10).
27. Centers for Disease Control and Prevention NCFEH. *Screening young children for lead poisoning: guidance for state and local health officials*. Atlanta, GA: USDHHS; 1997.
28. Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning. Recommendations for blood lead screening of young children enrolled in Medicaid: targeting a group at high risk. *MMWR*. 2000;49(RR-14):1-13.
29. Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning. *Preventing Lead Exposure in Young Children: A Housing-Based Approach to Primary Prevention of Lead Poisoning*. Atlanta, GA: U. S. DHHS; 2004.
30. Centers for Disease C, Prevention. Blood lead levels in residents of homes with elevated lead in tap water--District of Columbia, 2004. *MMWR*. 2004;53(12):268-270.
31. Gardella C. Lead exposure in pregnancy: a review of the literature and argument for routine prenatal screening. *Obstet Gynecol Surv*. 2001;56(4):231-238.
32. Rhainds M, Levallois P. Effects of maternal cigarette smoking and alcohol consumption on blood lead levels of newborns. *Am J Epidemiol*. 1997;145(3):250-257.
33. Harville EW, Hertz-Picciotto I, Schramm M, et al. Factors influencing the difference between maternal and cord blood lead. *Occup Environ Med*. 2005;62(4):263-269.
34. Klitzman S, Sharma A, Nicaj L, Vitkevich R, Leighton J. Lead poisoning among pregnant women in New York City: risk factors and screening practices. *J Urban Health*. 2002;79(2):225-237.
35. Lanphear BP, Dietrich KN, Berger O. Prevention of lead toxicity in US children. *Ambul Pediatr*. 2003;3(1):27-36.
36. Fatal pediatric lead poisoning--New Hampshire, 2000. *MMWR*. 2001;50(22):457-459.

37. Baghurst PA, McMichael AJ, Wigg NR, et al. Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study. *N Engl J Med.* 1992;327(18):1279-1284.
38. Cooney G, Bell A, Stravou C. Low level exposure to lead and neurobehavioural development: the Sydney Study at seven years. *Proceedings of Heavy Metals in the Environment Conference, Edinburgh.* 1991;Farmer JG, ed.(1):16-19.
39. Bellinger DC, Stiles KM, Needleman HL. Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study. *Pediatrics.* 1992;90(6):855-861.
40. Dietrich KN, Berger OG, Succop PA, Hammond PB, Bornschein RL. The developmental consequences of low to moderate prenatal and postnatal lead exposure: intellectual attainment in the Cincinnati Lead Study Cohort following school entry. *Neurotoxicol Teratol.* 1993;15(1):37-44.
41. Ernhart CB, Morrow-Tlucak M, Wolf AW, Super D, Drotar D. Low level lead exposure in the prenatal and early preschool periods: intelligence prior to school entry. *Neurotoxicol Teratol.* 1989;11(2):161-170.
42. Wasserman GA, Graziano JH, Factor-Litvak P, et al. Consequences of lead exposure and iron supplementation on childhood development at age 4 years. *Neurotoxicol Teratol.* 1994;16(3):233-240.
43. Wolf AW, Jimenez E, Lozoff B. No evidence of developmental III effects of low-level lead exposure in a developing country. *J Dev Behav Pediatr.* 1994;15(4):224-231.
44. Pocock SJ, Smith M, Baghurst P. Environmental lead and children's intelligence: a systematic review of the epidemiological evidence. *BMJ.* 1994;309(6963):1189-1197.
45. Chen A, Dietrich K, Ware JH, Radcliffe J, Rogan W. IQ and blood lead from 2 to 7 years of age: are the effects in older children the residual of high blood lead concentrations in 2-year-olds? *Environ Health Perspect.* 2005;113(5):597-601.
46. Needleman HL, Gatsonis CA. Low-level lead exposure and the IQ of children. A meta-analysis of modern studies. *JAMA.* 1990;263(5):673-678.
47. Winneke G, Brockhaus A, Ewers U, Kramer U, Neuf M. Results from the European multicenter study on lead neurotoxicity in children: implications for risk assessment. *Neurotoxicol Teratol.* 1990;12(5):553-559.
48. Winneke G, Beginn U, Ewert T, et al. Comparing the effects of perinatal and later childhood lead exposure on neuropsychological outcome. *Environ Res.* 1985;38(1):155-167.
49. Winneke G, Kramer U, Brockhaus A, et al. Neuropsychological studies in children with elevated tooth-lead concentrations. II. Extended study. *Int Arch Occup Environ Health.* 1983;51(3):231-252.
50. Winneke G, Brockhaus A, Collet W, Kramer U. Modulation of lead-induced performance deficit in children by varying signal rate in a serial choice reaction task. *Neurotoxicol Teratol.* 1989;11(6):587-592.
51. Hatzakis A, Kokkevi A, Katsouyanni K, al. e. Psychometric intelligence and attentional performance deficits in lead-exposed children. *Proceedings of the International Conference: heavy metals in the environment.* 1987;1:204-209.
52. Wigg NR. Low-level lead exposure and children. *J Paediatr Child Health.* 2001;37(5):423-425.
53. Bellinger DC. Lead. *Pediatrics.* 2004;113(4 Suppl):1016-1022.

54. Otto DA, Fox DA. Auditory and visual dysfunction following lead exposure. *Neurotoxicology*. 1993;14(2-3):191-207.
55. Cory-Slechta D. The behavioral toxicity of lead: problems and perspectives. *Adv Behav Pharmacol*. 1984;4:211-255.
56. Rice D. Lead-induced changes in learning: evidence for behavioral mechanisms from experimental animal studies. *Neurotoxicology*. 1993;14:167-178.
57. Koller K, Brown T, Spurgeon A, Levy L. Recent developments in low-level lead exposure and intellectual impairment in children. *Environ Health Perspect*. 2004;112(9):987-994.
58. Canfield RL, Gendle MH, Cory-Slechta DA. Impaired neuropsychological functioning in lead-exposed children. *Dev Neuropsychol*. 2004;26(1):513-540.
59. Lanphear BP, Dietrich K, Auinger P, Cox C. Cognitive deficits associated with blood lead concentrations <10 microg/dL in US children and adolescents. *Public Health Rep*. 2000;115(6):521-529.
60. Chiodo LM, Jacobson SW, Jacobson JL. Neurodevelopmental effects of postnatal lead exposure at very low levels. *Neurotoxicol Teratol*. 2004;26(3):359-371.
61. Lanphear B, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. *Environ Health Perspect*. 2005;113:894-899.
62. Ernhart CB, Wolf AW, Kennard MJ, Erhard P, Filipovich HF, Sokol RJ. Intrauterine exposure to low levels of lead: the status of the neonate. *Arch Environ Health*. 1986;41(5):287-291.
63. McMichael AJ, Vimpani GV, Robertson EF, Baghurst PA, Clark PD. The Port Pirie cohort study: maternal blood lead and pregnancy outcome. *J Epidemiol Community Health*. 1986;40(1):18-25.
64. Bellinger D, Leviton A, Rabinowitz M, Allred E, Needleman H, Schoenbaum S. Weight gain and maturity in fetuses exposed to low levels of lead. *Environ Res*. 1991;54(2):151-158.
65. Murphy MJ, Graziano JH, Popovac D, et al. Past pregnancy outcomes among women living in the vicinity of a lead smelter in Kosovo, Yugoslavia. *Am J Public Health*. 1990;80(1):33-35.
66. Lindbohm ML, Sallmen M, Anttila A, Taskinen H, Hemminki K. Paternal occupational lead exposure and spontaneous abortion. *Scand J Work Environ Health*. 1991;17(2):95-103.
67. Laudanski T, Sipowicz M, Modzelewski P, et al. Influence of high lead and cadmium soil content on human reproductive outcome. *Int J Gynaecol Obstet*. 1991;36(4):309-315.
68. Dietrich KN, Krafft KM, Bornschein RL, et al. Low-level fetal lead exposure effect on neurobehavioral development in early infancy. *Pediatrics*. 1987;80(5):721-730.
69. Factor-Litvak P, Graziano JH, Kline JK, et al. A prospective study of birth weight and length of gestation in a population surrounding a lead smelter in Kosovo, Yugoslavia. *Int J Epidemiol*. 1991;20(3):722-728.
70. Milman N, Christensen JM, Ibsen KK. Blood lead and erythrocyte zinc protoporphyrin in mothers and newborn infants. *Eur J Pediatr*. 1988;147(1):71-73.
71. Ernhart CB. A critical review of low-level prenatal lead exposure in the human: 1. Effects on the fetus and newborn. *Reprod Toxicol*. 1992;6(1):9-19.

72. Baghurst PA, Robertson EF, Oldfield RK, et al. Lead in the placenta, membranes, and umbilical cord in relation to pregnancy outcome in a lead-smelter community. *Environ Health Perspect.* 1991;90:315-320.
73. Andrews KW, Savitz DA, Hertz-Picciotto I. Prenatal lead exposure in relation to gestational age and birth weight: a review of epidemiologic studies. *Am J Ind Med.* 1994;26(1):13-32.
74. Rothenberg SJ, Schnaas L, Perroni E, Hernandez RM, Martinez S, Hernandez C. Pre- and postnatal lead effect on head circumference: a case for critical periods. *Neurotoxicol Teratol.* 1999;21(1):1-11.
75. Gonzalez-Cossio T, Peterson KE, Sanin LH, et al. Decrease in birth weight in relation to maternal bone-lead burden. *Pediatrics.* 1997;100(5):856-862.
76. Emory E, Pattillo R, Archibold E, Bayorh M, Sung F. Neurobehavioral effects of low-level lead exposure in human neonates. *Am J Obstet Gynecol.* 1999;181(1).
77. Emory E, Ansari Z, Pattillo R, Archibold E, Chevalier J. Maternal blood lead effects on infant intelligence at age 7 months. *Am J Obstet Gynecol.* 2003;188(4).
78. Rothenberg SJ, Poblano A, Schnaas L. Brainstem auditory evoked response at five years and prenatal and postnatal blood lead. *Neurotoxicol Teratol.* 2000;22(4):503-510.
79. Rothenberg SJ, Schnaas L, Salgado-Valladares M, et al. Increased ERG a- and b-wave amplitudes in 7- to 10-year-old children resulting from prenatal lead exposure. *Invest Ophthalmol Vis Sci.* 2002;43(6):2036-2044.
80. Chisolm JJ, Jr. The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. *J Pediatr.* 1968;73(1):1-38.
81. Pueschel SM, Kopito L, Schwachman H. Children with an increased lead burden. A screening and follow-up study. *JAMA.* 1972;222(4):462-466.
82. Nuyts GD, Daelemans RA, Jorens PG, Elseviers MM, Van de Vyver FL, De Broe ME. Does lead play a role in the development of chronic renal disease? *Nephrol Dial Transplant.* 1991;6(5):307-315.
83. Hu H. A 50-year follow-up of childhood plumbism. Hypertension, renal function, and hemoglobin levels among survivors. *Am J Dis Child.* 1991;145(6):681-687.
84. Bernard AM, Vyskocil A, Roels H, Kriz J, Kodl M, Lauwerys R. Renal effects in children living in the vicinity of a lead smelter. *Environ Res.* 1995;68(2):91-95.
85. Fels LM, Wunsch M, Baranowski J, et al. Adverse effects of chronic low level lead exposure on kidney function--a risk group study in children. *Nephrol Dial Transplant.* 1998;13(9):2248-2256.
86. Grandjean P, Hollnagel H, Hedegaard L, Christensen JM, Larsen S. Blood lead-blood pressure relations: alcohol intake and hemoglobin as confounders. *Am J Epidemiol.* 1989;129(4):732-739.
87. Elwood PC, Yarnell JW, Oldham PD, et al. Blood pressure and blood lead in surveys in Wales. *Am J Epidemiol.* 1988;127(5):942-945.
88. Schwartz J. Lead, blood pressure, and cardiovascular disease in men and women. *Environ Health Perspect.* 1991;91:71-75.
89. Moller L, Kristensen TS. Blood lead as a cardiovascular risk factor. *Am J Epidemiol.* 1992;136(9):1091-1100.
90. Dolenc P, Staessen JA, Lauwerys RR, Amery A. Short report: low-level lead exposure does not increase the blood pressure in the general population. Cadmibel Study Group. *J Hypertens.* 1993;11(5):589-593.

91. Hense HW, Filipiak B, Keil U. The association of blood lead and blood pressure in population surveys. *Epidemiology*. 1993;4:173-179.
92. Rabinowitz M, Bellinger D, Leviton A, Needleman H, Schoenbaum S. Pregnancy hypertension, blood pressure during labor, and blood lead levels. *Hypertension*. 1986;10(4):447-451.
93. Selbst SM, Sokas RK, Henretig FM, Weller SC, Tershakovec AM. The effect of blood lead on blood pressure in children. *J Environ Pathol Toxicol Oncol*. 1993;12(4):213-218.
94. Schwartz J, Angle C, Pitcher H. Relationship between childhood blood lead levels and stature. *Pediatrics*. 1986;77(3):281-288.
95. Frisancho AR, Ryan AS. Decreased stature associated with moderate blood lead concentrations in Mexican-American children. *Am J Clin Nutr*. 1991;54(3):516-519.
96. Shukla R, Dietrich KN, Bornschein RL, Berger O, Hammond PB. Lead exposure and growth in the early preschool child: a follow-up report from the Cincinnati Lead Study. *Pediatrics*. 1991;88(5):886-892.
97. Greene T, Ernhart CB. Prenatal and preschool age lead exposure: relationship with size. *Neurotoxicol Teratol*. 1991;13(4):417-427.
98. Rothenberg SJ, Manalo M, Jiang J, et al. Blood lead level and blood pressure during pregnancy in South Central Los Angeles. *Arch Environ Health*. 1999;54(6):382-389.
99. Rothenberg SJ, Kondrashov V, Manalo M, et al. Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. *Am J Epidemiol*. 2002;156(12):1079-1087.
100. Magri J, Sammut M, Savona-Ventura C. Lead and other metals in gestational hypertension. *Int J Gynaecol Obstet*. 2003;83(1):29-36.
101. Dawson EB, Evans DR, Kelly R, Van Hook JW. Blood cell lead, calcium, and magnesium levels associated with pregnancy-induced hypertension and preeclampsia. *Biol Trace Elem Res*. 2000;74(2):107-116.
102. Jacobson BE, Lockitch G, Quigley G. Improved sample preparation for accurate determination of low concentrations of lead in whole blood by graphite furnace analysis. *Clin Chem*. 1991;37(4):515-519.
103. Parsons P, Raciti KA, Esernio-Jenssen D. Evaluation and improvement of sample collection procedures for the determination of blood lead. *Third semi-annual report to the Center for Environmental Health and Injury Control*. 1993;Center for Disease Control and Prevention(Atlanta: Centers for Disease Control and Prevention).
104. Schlenker TL, Fritz CJ, Mark D, et al. Screening for pediatric lead poisoning. Comparability of simultaneously drawn capillary and venous blood samples. *JAMA*. 1994;271(17):1346-1348.
105. Schonfeld DJ, Cullen MR, Rainey PM, et al. Screening for lead poisoning in an urban pediatric clinic using samples obtained by fingerstick. *Pediatrics*. 1994;94(2 Pt 1):174-179.
106. Lyngbye T, Jorgensen PJ, Grandjean P, Hansen ON. Validity and interpretation of blood lead levels: a study of Danish school children. *Scand J Clin Lab Invest*. 1990;50(4):441-449.
107. Schonfeld DJ, Rainey PM, Cullen MR, Showalter DR, Cicchetti DV. Screening for lead poisoning by fingerstick in suburban pediatric practices. *Arch Pediatr Adolesc Med*. 1995;149(4):447-450.

108. Parsons PJ. Monitoring human exposure to lead: an assessment of current laboratory performance for the determination of blood lead. *Environ Res.* 1992;57(2):149-162.
109. Blumenthal HT, Flanigan GD, Jr., Mayfield R. Studies on lead exposure in patients of a neighborhood health center: Part I: Pediatric patients. *J Natl Med Assoc.* 1991;83:1065-1072.
110. Mahaffey KR, Annest JL. Association of erythrocyte protoporphyrin with blood lead level and iron status in the second National Health and Nutrition Examination Survey, 1976-1980. *Environ Res.* 1986;41(1):327-338.
111. Debaun MR, Sox HC. Setting the optimal erythrocyte protoporphyrin screening decision threshold for lead poisoning: a decision analytic approach. *Pediatrics.* 1991;88:121-131.
112. Parsons PJ, Reilly AA, Hussain A. Observational study of erythrocyte protoporphyrin screening test for detecting low lead exposure in children: impact of lowering the blood lead action threshold. *Clin Chem.* 1991;37(2):216-225.
113. McElvaine MD, Orbach HG, Binder S, Blanksma LA, Maes EF, Krieg RM. Evaluation of the erythrocyte protoporphyrin test as a screen for elevated blood lead levels. *J Pediatr.* 1991;119(4):548-550.
114. Leung FY, Bradley C, Pellar TG. Reference intervals for blood lead and evaluation of zinc protoporphyrin as a screening test for lead toxicity. *Clin Biochem.* 1993;26(6):491-496.
115. Rolfe PB, Marcinak JF, Nice AJ, Williams RH. Use of zinc protoporphyrin measured by the Protofluor-Z hematofluorometer in screening children for elevated blood lead levels. *Am J Dis Child.* 1993;147(1):66-68.
116. Marcus AH, Schwartz J. Dose-response curves for erythrocyte protoporphyrin vs. blood lead: effects of iron status. *Environ Res.* 1987;44(2):221-227.
117. Guthrie R, Orfanos A, Widger K, Luskin B, Francemone C, Nadler D. Screening suburban/rural children for lead exposure, iron deficiency. *Am J Public Health.* 1988;78(7):856-857.
118. Tejada DM, Wyatt DD, Rostek BR, Solomon WB. Do questions about lead exposure predict elevated lead levels? *Pediatrics.* 1994;93(2):192-194.
119. Binns HJ, LeBailly SA, Poncher J, Kinsella TR, Saunders SE. Is there lead in the suburbs? Risk assessment in Chicago suburban pediatric practices. Pediatric Practice Research Group. *Pediatrics.* 1994;93(2):164-171.
120. Nordin JD, Rolnick SJ, Griffin JM. Prevalence of excess lead absorption and associated risk factors in children enrolled in a Midwestern health maintenance organization. *Pediatrics.* 1994;93(2):172-177.
121. Schaffer SJ, Szilagyi PG, Weitzman M. Lead poisoning risk determination in an urban population through the use of a standardized questionnaire. *Pediatrics.* 1994;93(2):159-163.
122. Rooney BL, Hayes EB, Allen BK, Strutt PJ. Development of a screening tool for prediction of children at risk for lead exposure in a Midwestern clinical setting. *Pediatrics.* 1994;93(2):183-187.
123. Striph KB. Prevalence of lead poisoning in a suburban practice. *J Fam Pract.* 1995;41(1):65-71.
124. Centers for Disease Control and Prevention. *Preventing lead poisoning in young children. A statement by the Centers for Disease Control - October 1991.* Atlanta: Department of Health and Human Services; 1991.

125. France EK, Gitterman BA, Melinkovich P, Wright RA. The accuracy of a lead questionnaire in predicting elevated pediatric blood lead levels. *Arch Pediatr Adolesc Med.* 1996;150(9):958-963.
126. Kazal LA, Jr. The failure of CDC screening questionnaire to efficiently detect elevated lead levels in a rural population of children. *J Fam Pract.* 1997;45(6):515-518.
127. Muniz MA, Dundas R, Mahoney MC. Evaluation of a childhood lead questionnaire in predicting elevated blood lead levels in a rural community. *J Rural Health.* 2003;19(1):15-19.
128. Robin LF, Beller M, Middaugh JP. Statewide assessment of lead poisoning and exposure risk among children receiving Medicaid services in Alaska. *Pediatrics.* 1997;99(4).
129. Schaffer SJ, Kincaid MS, Endres N, Weitzman M. Lead poisoning risk determination in a rural setting. *Pediatrics.* 1996;97(1):84-90.
130. Sargent JD, Dalton M, Klein RZ. Diagnostic testing unwarranted for children with blood lead 10 to 14 microg/dL. *Pediatrics.* 1999;103(4).
131. Lanphear B, Hornung R, Ho M. Screening housing to prevent lead toxicity in children. . *Public Health Rep.* 2005;120:305-310.
132. McCusker J. Longitudinal changes in blood lead level in children and their relationship to season, age, and exposure to paint or plaster. *Am J Public Health.* 1979;69(4):348-352.
133. Reigart JR, Whitlock NH. Longitudinal observations of the relationship between free erythrocyte porphyrins and whole blood lead. *Pediatrics.* 1976;57(1):54-59.
134. Sachs HK, Blanksma LA, Murray EF, O'Connell MJ. Ambulatory treatment of lead poisoning: report of 1,155 cases. *Pediatrics.* 1970;46(3):389-396.
135. Sachs HK. Effect of a screening program on changing patterns of lead poisoning. *Environ Health Perspect.* 1974;7:41-45.
136. Browder A, Joselow M, Louriya DB, Lavenhar M, Foster J. Evaluation of screening programs for childhood lead poisoning by analysis of hospital admissions. *Am J Public Health.* 1974;64(9):914-915.
137. Rogan W. The Treatment of Lead-exposed Children (TLC) trial: design and recruitment for a study of the effect of oral chelation on growth and development in toddlers. *Paediatr Perinat Epidemiol.* 1998;12:313-333.
138. Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. *N Engl J Med.* 2001;344(19):1421-1426.
139. Liu X, Dietrich KN, Radcliffe J, Ragan NB, Rhoads GG, Rogan WJ. Do children with falling blood lead levels have improved cognition? *Pediatrics.* 2002;110(4):787-791.
140. Dietrich KN, Ware JH, Salganik M, et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. *Pediatrics.* 2004;114(1):19-26.
141. Peterson KE, Salganik M, Campbell C, et al. Effect of succimer on growth of preschool children with moderate blood lead levels. *Environ Health Perspect.* 2004;112(2):233-237.
142. Ruff HA, Bijur PE, Markowitz M, Ma YC, Rosen JF. Declining blood lead levels and cognitive changes in moderately lead-poisoned children. *JAMA.* 1993;269(13):1641-1646.

143. Markowitz ME, Bijur PE, Ruff H, Rosen JF. Effects of calcium disodium versenate (CaNa₂EDTA) chelation in moderate childhood lead poisoning. *Pediatrics*. 1993;92(2):265-271.
144. Rogan W. Safety and efficacy of succimer in toddlers with blood lead levels of 20-44 ug/dL. *Pediatr Res*. 2000;48(5):593-599.
145. Graziano JH, Lolocono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. *J Pediatr*. 1992;120(1):133-139.
146. Graziano JH, Lolocono NJ, Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. *J Pediatr*. 1988;113(4):751-757.
147. Shannon M, Graef J, Lovejoy FH, Jr. Efficacy and toxicity of D-penicillamine in low-level lead poisoning. *J Pediatr*. 1988;112(5):799-804.
148. Liebelt EL, Shannon M, Graef JW. Efficacy of oral meso-2,3-dimercaptosuccinic acid therapy for low-level childhood plumbism. *J Pediatr*. 1994;124(2):313-317.
149. Shannon M, Grace A, Graef JW. Use of penicillamine in children with small lead burdens. *N Engl J Med*. 1989;321(14):979-980.
150. Besunder JB, Anderson RL, Super DM. Short-term efficacy of oral dimercaptosuccinic acid in children with low to moderate lead intoxication. *Pediatrics*. 1995;96(4 Pt 1):683-687.
151. O'Connor ME, Rich D. Children with moderately elevated lead levels: is chelation with DMSA helpful? *Clin Pediatr*. 1999;38(6):325-331.
152. Chisolm JJ, Jr. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. *J Toxicol Clin Toxicol*. 2000;38(4):365-375.
153. Moel DI, Sachs HK, Drayton MA. Slow, natural reduction in blood lead level after chelation therapy for lead poisoning in childhood. *Am J Dis Child*. 1986;140(9):905-908.
154. Chisolm JJ, Jr. Chelation therapy in children with subclinical plumbism. *Pediatrics*. 1974;53(3):441-443.
155. Vitale LF, Rosalinas-Bailon A, Folland D, Brennan JF, McCormick B. Oral penicillamine therapy for chronic lead poisoning in children. *J Pediatr*. 1973;83(6):1041-1045.
156. Marcus SM. Experience with D-penicillamine in treating lead poisoning. *Vet Hum Toxicol*. 1982;24(1):18-20.
157. Markowitz ME, Bijur PE, Ruff HA, Balbi K, Rosen JF. Moderate lead poisoning: trends in blood lead levels in unchelated children. *Environ Health Perspect*. 1996;104(9):968-972.
158. Office of Policy Development and Research Department of Housing and Urban Development. Lead-based paint abatement demonstration (FHA). *Washington, DC: Department of Housing and Urban Development*. 1991;(Publication no. HUD-1316-PDR).
159. Farfel MR, Chisolm JJ, Jr., Rohde CA. The longer-term effectiveness of residential lead paint abatement. *Environ Res*. 1994;66(2):217-221.
160. Clark S, Grote J, Wilson J, et al. Occurrence and determinants of increases in blood lead levels in children shortly after lead hazard control activities. *Environ Res*. 2004;96(2):196-205.

161. Rhoads G, Ettinger A, Weisel C, et al. The effect of dust lead control on blood lead in toddlers: a randomized trial. *Pediatrics*. 1999;103(3):551-555.
162. Taha T, Kanarek MS, Schultz BD, Murphy A. Low-cost household paint abatement to reduce children's blood lead levels. *Environ Res*. 1999;81(4):334-338.
163. Aschengrau A, Hardy S, Mackey P, Pultinas D. The impact of low technology lead hazard reduction activities among children with mildly elevated blood lead levels. *Environ Res*. 1998;79(1):41-50.
164. Leighton J, Klitzman S, Sedlar S, Matte T, Cohen NL. The effect of lead-based paint hazard remediation on blood lead levels of lead poisoned children in New York City. *Environ Res*. 2003;92(3):182-190.
165. Haynes E, Lanphear BP, Tohn E, Farr N, Rhoads GG. The effect of interior lead hazard controls on children's blood lead concentrations: a systematic evaluation. *Environ Health Perspect*. 2002;110(1):103-107.
166. Yiin LM, Liroy PJ, Rhoads GG. Impact of home carpets on childhood lead intervention study. *Environ Res*. 2003;92(2):161-165.
167. Campbell C, Schwarz DF, Rich D, Dockery DW. Effect of a follow-up professional home cleaning on serial dust and blood lead levels of urban children. *Arch Environ Health*. 2003;58(12):771-780.
168. Swindell SL, Charney E, Brown MJ, Delaney J. Home abatement and blood lead changes in children with class III lead poisoning. *Clin Pediatr*. 1994;33(9):536-541.
169. Brown MJ, Gardner J, Sargent JD, Swartz K, Hu H, Timperi R. The effectiveness of housing policies in reducing children's lead exposure. *Am J Public Health*. 2001;91(4):621-624.
170. Galke W, Clark S, Wilson J, et al. Evaluation of the HUD lead hazard control grant program: early overall findings. *Environ Res*. 2001;86(2):149-156.
171. Strauss W, Pivetz T, Ashley P, Menkedick J, Slone E, Cameron S. Evaluation of lead hazard control treatments in four Massachusetts communities through analysis of blood-lead surveillance data. *Environ Res* 2005;in press.
172. Foster JD, Louria DB, Stinson L. Influence of documented lead poisoning on environmental modification programs in Newark, New Jersey. *Arch Environ Health*. 1979;34(5):368-371.
173. Weitzman M, Aschengrau A, Bellinger D, Jones R, Hamlin JS, Beiser A. Lead-contaminated soil abatement and urban children's blood lead levels. *JAMA*. 1993;269(13):1647-1654.
174. Environmental Protection Agency. Three city urban soil lead abatement demonstration project (fact sheet). *Washington, DC: Environmental Protection Agency*. 1992;(Publication no. 9355.4-10FSA).
175. Farrell KP, Brophy MC, Chisolm JJ, Jr., Rohde CA, Strauss WJ. Soil lead abatement and children's blood lead levels in an urban setting. *Am J Public Health*. 1998;88(12):1837-1839.
176. Charney E, Kessler B, Farfel M, Jackson D. Childhood lead poisoning. A controlled trial of the effect of dust-control measures on blood lead levels. *N Engl J Med*. 1983;309(18):1089-1093.
177. Jordan CM, Yust BL, Robison LL, Hannan P, Deinard AS. A randomized trial of education to prevent lead burden in children at high risk for lead exposure: efficacy as measured by blood lead monitoring. *Environ Health Perspect*. 2003;111(16):1947-1951.

178. Lanphear BP, Howard C, Eberly S, et al. Primary prevention of childhood lead exposure: A randomized trial of dust control. *Pediatrics*. 1999;103(4 Pt 1):772-777.
179. Schultz B, Pawel D, Murphy A. A retrospective examination of in-home educational visits to reduce childhood lead levels. *Environ Res*. 1999;80(4):364-368.
180. Kimbrough R, LeVois M, Webb D. Survey of lead exposure around a closed lead smelter. *Pediatrics*. 1995;95(4):550-554.
181. Porru S, Donato F, Apostoli P, Coniglio L, Duca P, Alessio L. The utility of health education among lead workers: the experience of one program. *Am J Ind Med*. 1993;23(3):473-481.
182. Aschengrau A, Beiser A, Bellinger D, Copenhafer D, Weitzman M. The impact of soil lead abatement on urban children's blood lead levels: phase II results from the Boston Lead-In-Soil Demonstration Project. *Environ Res*. 1994;67(2):125-148.
183. Aschengrau A, Beiser A, Bellinger D, Copenhafer D, Weitzman M. Residential lead-based-paint hazard remediation and soil lead abatement: their impact among children with mildly elevated blood lead levels. *Am J Public Health*. 1997;87(10):1698-1702.
184. Lanphear BP, Succop P, Roda S, Henningsen G. The effect of soil abatement on blood lead levels in children living near a former smelting and milling operation. *Public Health Rep*. 2003;118(2):83-91.
185. Dalton MA, Sargent JD, O'Connor GT, Olmstead EM, Klein RZ. Calcium and phosphorus supplementation of iron-fortified infant formula: no effect on iron status of healthy full-term infants. *Am J Clin Nutr*. 1997;65(4):921-926.
186. Gallicchio L, Scherer RW, Sexton M. Influence of nutrient intake on blood lead levels of young children at risk for lead poisoning. *Environ Health Perspect*. 2002;110(12).
187. Hammad TA, Sexton M, Langenberg P. Relationship between blood lead and dietary iron intake in preschool children. A cross-sectional study. *Ann Epidemiol*. 1996;6(1):30-33.
188. Lucas SR, Sexton M, Langenberg P. Relationship between blood lead and nutritional factors in preschool children: a cross-sectional study. *Pediatrics*. 1996;97(1):74-78.
189. Markowitz ME, Sinnott M, Rosen JF. A randomized trial of calcium supplementation for childhood lead poisoning. *Pediatrics*. 2004;113(1 Pt 1).
190. Sargent JD, Dalton MA, O'Connor GT, Olmstead EM, Klein RZ. Randomized trial of calcium glycerophosphate-supplemented infant formula to prevent lead absorption. *Am J Clin Nutr*. 1999;69(6):1224-1230.
191. Schell LM, Denham M, Stark AD, Ravenscroft J, Parsons P, Schulte E. Relationship between blood lead concentration and dietary intakes of infants from 3 to 12 months of age. *Environ Res*. 2004;96(3):264-273.
192. Schell LM, Denham M, Stark AD, et al. Maternal blood lead concentration, diet during pregnancy, and anthropometry predict neonatal blood lead in a socioeconomically disadvantaged population. *Environ Health Perspect*. 2003;111(2):195-200.
193. Simon JA, Hudes ES. Relationship of ascorbic acid to blood lead levels. *JAMA*. 1999;281(24):2289-2293.
194. Zierold KM, Anderson H. Trends in blood lead levels among children enrolled in the Special Supplemental Nutrition Program for Women, Infants, and Children from 1996 to 2000. *Am J Public Health*. 2004;94(9):1513-1515.
195. Lanphear BP, Hornung R, Ho M, Howard CR, Eberly S, Knauf K. Environmental lead exposure during early childhood. *J Pediatr*. 2002;140(1):40-47.

196. Haynes E, Kalkwarf H, Hornung R, al. e. Vitamin D Fok1 polymorphism and blood lead concentration in children. *Environ Health Perspect.* 2003;111:1665-1669.
197. Bellinger D. Teratogen Update: Lead and Pregnancy. *Birth Defects Research.* 2004;(Part A) 73:409-420.
198. Glotzer DE, Bauchner H. Management of childhood lead poisoning: a survey. *Pediatrics.* 1992;89:614-618.
199. Markowitz ME, Rosen JF. Need for the lead mobilization test in children with lead poisoning. *J Pediatr.* 1991;119(2):305-310.
200. Farfel MR, Chisolm JJ, Jr. Health and environmental outcomes of traditional and modified practices for abatement of residential lead-based paint. *Am J Public Health.* 1990;80(10):1240-1245.
201. Amitai Y, Brown MJ, Graef JW, Cosgrove E. Residential deleading: effects on the blood lead levels of lead-poisoned children. *Pediatrics.* 1991;88(5):893-897.
202. Amitai Y, Graef JW, Brown MJ, Gerstle RS, Kahn N, Cochrane PE. Hazards of 'deleading' homes of children with lead poisoning. *Am J Dis Child.* 1987;141(7):758-760.
203. Rey-Alvarez S, Menke-Hargrave T. Deleading dilemma: pitfall in the management of childhood lead poisoning. *Pediatrics.* 1987;79(2):214-217.
204. Feldman RG. Urban lead mining: lead intoxication among deleaders. *N Engl J Med.* 1978;298(20):1143-1145.
205. Chisolm JJ, Jr. Treatment of acute lead intoxication--choice of chelating agents and supportive therapeutic measures. *Clin Toxicol.* 1970;3(4):527-540.
206. Moel DI, Kumar K. Reversible nephrotoxic reactions to a combined 2,3-dimercapto-1-propanol and calcium disodium ethylenediaminetetraacetic acid regimen in asymptomatic children with elevated blood lead levels. *Pediatrics.* 1982;70(2):259-262.
207. Shannon MW, Townsend MK. Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning. *Ann Pharmacother.* 2000;34(1):15-18.
208. Mann KV, Travers JD. Succimer, an oral lead chelator. *Clin Pharm.* 1991;10(12):914-922.
209. Lane WG, Kemper AR, American College of Preventive M. American College of Preventive Medicine Practice Policy Statement. Screening for elevated blood lead levels in children. *Am J Prev Med.* 2001;20(1):78-82.
210. American Academy of Pediatrics Committee on Environmental Health. Screening for elevated blood lead levels. *Pediatrics.* 1998;101(6):1072-1078.
211. Ellis MR, Kane KY. Lightening the lead load in children. *Am Fam Physician.* 2000;62(3):545-554.
212. Centers for Medicare and Medicaid Services. Medicaid and EPSDT. Added 6.8.05; <http://www.cms.hhs.gov/medicaid/epsdt/default.asp>. Accessed June 5, 2005.
213. Markowitz M, Rosen JF, Clemente I. Clinician follow-up of children screened for lead poisoning. *Am J Public Health.* 1999;89(7):1088-1090.
214. Campbell JR, Schaffer SJ, Szilagyi PG, O'Connor KG, Briss P, Weitzman M. Blood lead screening practices among US pediatricians. *Pediatrics.* 1996;98(3 Pt 1):372-377.
215. New York State Department of Health and American College of Obstetricians and Gynecologists District II. *Lead poisoning prevention guidelines for prenatal care providers.* Albany, NY: New York City Department of Health; 1995.

216. Pirkle JL, Brody DJ, Gunter EW, et al. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES) *JAMA*. 1994;272(4):284-291.
217. Annett JL, Pirkle JL, Makuc D, Neese JW, Bayse DD, Kovar MG. Chronological trend in blood lead levels between 1976 and 1980. *N Engl J Med*. 1983;308(23):1373-1377.
218. Centers for Disease Control and Prevention. Blood lead levels - United States, 1988-1991. *MMWR*. 1994;43:545-548.
219. Hayes EB, McElvaine MD, Orbach HG, Fernandez AM, Lyne S, Matte TD. Long-term trends in blood lead levels among children in Chicago: relationship to air lead levels. *Pediatrics*. 1994;93(2):195-200.
220. Davis JM, Elias RW, Grant LD. Current issues in human lead exposure and regulation of lead. *Neurotoxicology*. 1993;14(2-3):15-27.
221. Galal-Gorchev H. Dietary intake, levels in food and estimated intake of lead, cadmium, and mercury. *Food Addit Contam*. 1993;10(1):115-128.
222. Prpic-Majic D, Pongracic J, Hrsak J, Pizent A. A follow-up study in a lead smelter community following the introduction of an effective pollution control system. *Isr J Med Sci*. 1992;28(8-9):548-556.
223. Yankel AJ, von Lindern IH, Walter SD. The Silver Valley lead study: the relationship between childhood blood lead levels and environmental exposure. *J Air Pollut Control Assoc*. 1977;27(8):763-767.
224. Department of Health and Human Services, Department of Housing and Urban Development, and Environmental Protection Agency. Report of the Interagency Task Force on the Prevention of Lead Poisoning: a report to Congress. *Washington, DC: Department of Housing and Urban Development*. 1993.

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Aims	Study Design	Type of Intervention	N	
Besunder, 1995 ¹⁵⁰	To determine the short-term efficacy of DMSA in mild to moderate lead intoxication	Retrospective case-series	Chelation with DMSA and abatement of domestic lead hazards	46 treated, 18 excluded, N = 28	Regional treatment hospital,
Chisolm, 2000 ¹⁵²	Assess safety and efficacy of DMSA	Open label non-comparative (case-series)	Chelation with DMSA, relocation to lead-safe housing	59	Regional referral center MD
Dietrich, 2004 ¹⁴⁰	To assess neurobehavioral outcomes of children in the TLC study at 7 years of age.	Randomized multicenter, placebo controlled, double-blind trial	Chelation with DMSA after domestic cleaning with HEPA vacuum and damp cloth wiping	1854 evaluated, 780 randomized	Multicenter Cincinnati Newark,
Liebelt, 1994 ¹⁴⁸	To compare effect of DMSA treatment in children with initial blood lead level < 45 ug and > 45 ug	Retrospective cohort study	Chelation with DMSA	30	Regional treatment children's MA

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria
Besunder, 1995 ¹⁵⁰	Referral population, 35% African American, 10% Hispanic	Housing	25-49 ug/dl	Convenience sample. Children receiving 19 days of DMSA treatment during 6/91 to 5/93, with initial blood lead level between 25 and 49 ug/dl. Exclusion criteria: drug cosponsored trial (N=14), prior (previous 28 days) chelation therapy, concomitant chelating agent (EDTA, N=3), documented noncompliance (N=1).
Chisolm, 2000 ¹⁵²	Children ages 12-65 months	Housing	25-70 ug/dl	Convenience sample. Children 12-72 months old (actual range 12-65 months), with initial blood lead level 25-120 ug/dl (actual range 25-70 ug/dl), residing in lead-safe housing for duration of study, asymptomatic, having no other disease or other lead treatment in 2 prior months
Dietrich, 2004 ¹⁴⁰	Children ages 12-33 months, 77% African-American. Most had poor, single mothers and lived in older, poorly maintained residences.	Housing	20-44 ug/dl	Children ages 12-33 months with blood lead level 20-44 ug/dl on two occasions, living in a residence suitable for lead dust reduction. Recruitment varied by location. Patients were randomized by strata to treatment or placebo.
Liebelt, 1994 ¹⁴⁸	Ages 5-161 months (mean 34 months)	Housing	Range=20-60 ug/dl. GP1 (N=23) < 45 ug (mean = 31 ug) , GP2 (N=7) > 45 ug (mean=51 ug)	30 consecutive children (convenience sample) who received DMSA during a 15 month period. Indications for DMSA use: 11 = blood lead level > 45 ug/dl, 11 =complications resulting from use of pencillamine (another chelator), 1=chronic renal failure thought to preclude penicillamine use, 7 = failure of penicillamine and EDTA (persistent elevated blood lead level)

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Duration of Follow-up	Interventions Described	Outcomes Assessed	Results
Besunder, 1995 ¹⁵⁰	80 days	DMSA 10 mg/kg every 8 hours for 5 days, followed by 10 mg/kg every 12 hours for 14 days	Blood lead level, ZPP	Blood lead level: post-treatment (day 18) -43% (\pm 20.8%), 80 Days -31% (\pm 20.2%); ZPP post-treatment (day 18) -12% (\pm 21.7%), 80 days -32% (\pm 21.9%)
Chisolm, 2000 ¹⁵²	21 days	1050 mg/ m ² /day DMSA in three divided doses for five days, followed by 700 mg/ m ² / day in two dived doses for 21-23 days	Blood lead level	Mean blood lead level decreased to below 35% of pretreatment value after 4 weeks of DMSA treatment, and rebounded to 58% of pre-treatment level 2-3 weeks after cessation of therapy
Dietrich, 2004 ¹⁴⁰	6 years (until 7 years of age)	DMSA treatment lasting 26 days, dose based on body surface area; treatment repeated up to 3 times for persistently elevated blood lead level. Domestic cleaning with HEPA vacuum and damp cloth wiping	Cognition, behavior, learning and memory, attention, neurmotor--a battery of tests	No statistically significant difference in neurobehavioral outcomes except DMSA-treated children did worse on attention/executive function:
Liebelt, 1994 ¹⁴⁸	6 months	DMSA 30 mg/kg daily divided into 3 doses for five days, followed by 20 mg/kg daily in two divided doses for 14 days	Blood lead level, ZPP, AST, ALT	GP1 (<45 ug): mean blood lead level declined to 60% (19ug/dl) of pretreatment level during treatment, and rebounded (22 days after termination of treatment) to 74% of pretreatment levels, a net 26% reduction in mean blood lead level; GP2(>45ug): mean blood lead level declined to 58% (30 ug/dl) during treatment, and rebounde (18 days after termination of treatment) to 69% of pretreatment level, a net 31% decrease in mean blood lead level.

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Besunder, 1995 ¹⁵⁰	Neutropenia (N=1)	No control group, cannot exclude other intervention (abatement of domestic lead hazards prior to treatment)	Case series; non-controlled study.
Chisolm, 2000 ¹⁵²	Elevated alkaline phosphatase levels (n=2), eosinophilia (N=1)		Case series; non-controlled study.
Dietrich, 2004 ¹⁴⁰	No statistically significant difference compared to placebo. Excess noted: trauma, scalp rashes, neutropenia/thrombocytopenia, elevated ALT.	High quality	Good
Liebelt, 1994 ¹⁴⁸	Vomiting/diarrhea (N=1), mildly but statistically significantly increased ALT levels (mean 26 ± 3 mU/ml) (N=17)	No statistically significant difference in mean blood lead level percentage decrease between groups. Similar percentage reduction in both groups. Absolute reduction of blood lead level greater in high blood lead level group.	Case series; non-controlled study.

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Aims	Study Design	Type of Intervention	N	
Liu, 2002 ¹³⁹	A reanalysis of TLC data using change in blood lead level as independent variable (TLC trial)	Randomized multicenter, placebo controlled, double-blind trial	Chelation with DMSA after domestic cleaning with HEPA vacuum and damp cloth wiping	1854 evaluated, 780 randomized, 741 reanalyzed for this study	Multicent Cincinnati, Newark,
Markowitz, 1996 ¹⁵⁷	To determine the pattern of change in blood Pb (BPb) levels in the absence of chelation therapy	non-compatible study, cross sectional	observation, education	79 (206 eligible, 113 enrolled, 79 completed)	regional NY

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria
Liu, 2002 ¹³⁹	Children ages 12-33 months, 77% African-American. Most had poor, single mothers and lived in older, poorly maintained residences.	Housing	20-44 ug/dl	Children ages 12-33 months with blood lead level 20-44 ug/dl on two occasions, living in a residence suitable for lead dust reduction. Recruitment varied by location. Patients were randomized by strata to treatment or placebo.
Markowitz, 1996 ¹⁵⁷	Low income, inner city, 2/3 Hispanic 1/3 African American	Housing	25-55 ug/dl	Ages 1-7, blood lead level 25-55 ug, negative EDTA mobilization test, no prior chelation therapy, no neurobehavioral disorders from other causes

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Duration of Follow-up	Interventions Described	Outcomes Assessed	Results
Liu, 2002 ¹³⁹	36 months	DMSA treatment lasting 26 days, dose based on body surface area; treatment repeated up to 3 times for persistently elevated blood lead level. Domestic cleaning with HEPA vacuum and damp cloth wiping	Change in cognitive function by change in blood lead level	Six months after treatment, blood lead level had fallen a similar amount in both DMSA and placebo groups. There was no association between change in blood lead level and change in cognitive test score. blood lead level continued to fall, but at 36 months after treatment, cognitive test scores improved 4.0 points for every 10 ug/dl drop in blood lead level in the placebo group only. This implies that factors other than declining blood lead levels per se are responsible for the cognitive improvement. The data do not support the hypothesis that lead-induced cognitive defects are reversible by chelation therapy.
Markowitz, 1996 ¹⁵⁷	6 months	Eligible children received the following interventions: notification of the health department to remediate lead hazards; reinforced educational efforts about the toxicity sources and treatment of Pb during 10 clinic and 3 home visits; and iron therapy for children with ferritin levels less than 16 g/l. To quantify the lead paint hazards in the home, we combined a visual rating of the surfaces (intact to peeling) with an X-ray fluorescence (XRF) measurement of the lead content of the painted surface. The sum of these assessments is termed the home environmental score (HES).	Blood lead level	blood lead level declined 27% on average over 6 months. In 2/3, blood lead level declined to < 25 ug/dl, in 7% blood lead level declined to <15 ug/dl

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Liu, 2002 ¹³⁹	No statistically significant difference compared to placebo. Excess noted: trauma, scalp rashes, neutropenia/thrombocytopenia, elevated ALT.	Suggests that chelation may have adverse effect on cognitive development.	Good
Markowitz, 1996 ¹⁵⁷	ND	Mixed intervention. Describes home assesment tool (HES: home environmental score)	Case series; non-controlled study.

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Aims	Study Design	Type of Intervention	N	
O'Connor, 1999 ¹⁵¹	To determine the effectiveness of DMSA and environmental modification vs. placebo and environmental modification	Randomized placebo-controlled double-blind trial	Chelation with DMSA, domestic cleaning and repair	39	Urban ch Cleveland
Peterson, 2004 ¹⁴¹	To determine if chelation would have beneficial effect on growth in lead-exposed children (TLC trial)	Randomized multicenter, placebo controlled, double-blind trial	Chelation with DMSA after domestic cleaning with HEPA vacuum and damp cloth wiping	1854 evaluated, 780 randomized	Multicent Cincinnati Newark,
Rogan, 1998 ¹³⁷	Describes study design/methods of TLC trial	Randomized multicenter, placebo controlled, double-blind trial	Chelation with DMSA after domestic cleaning with HEPA vacuum and damp cloth wiping	1854 evaluated, 780 randomized	Multicent Cincinnati Newark,
Rogan, 2000 ¹⁴⁴	To determine the efficacy of DMSA (TLC trial)	Randomized multicenter, placebo controlled, double-blind trial	Chelation with DMSA after domestic cleaning with HEPA vacuum and damp cloth wiping	1854 evaluated, 780 randomized	Multicent Cincinnati Newark,

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria
O'Connor, 1999 ¹⁵¹	Low-income African-American inner city children 2.5-5 years old	Housing	30-45 ug/dl	Recruited from urban children's hospital, pediatric clinic or from referral practice of author. Exclusion criteria: previously high blood lead level (> 45 ug/dl) with chelation or history of numerous missed scheduled appointments or difficulty contacting family.
Peterson, 2004 ¹⁴¹	Children ages 12-33 months, 77% African-American. Most had poor, single mothers and lived in older, poorly maintained residences.	Housing	20-44 ug/dl	Children ages 12-33 months with blood lead level 20-44 ug/dl on two occasions, living in a residence suitable for lead dust reduction. Recruitment varied by location. Patients were randomized by strata to treatment or placebo.
Rogan, 1998 ¹³⁷	Children ages 12-33 months, 77% African-American. Most had poor, single mothers and lived in older, poorly maintained residences.	Housing	20-44 ug/dl	Children ages 12-33 months with blood lead level 20-44 ug/dl on two occasions, living in a residence suitable for lead dust reduction. Recruitment varied by location. Patients were randomized by strata to treatment or placebo.
Rogan, 2000 ¹⁴⁴	Children ages 12-33 months, 77% African-American. Most had poor, single mothers and lived in older, poorly maintained residences.	Housing	20-44 ug/dl	Children ages 12-33 months with blood lead level 20-44 ug/dl on two occasions, living in a residence suitable for lead dust reduction. Recruitment varied by location. Patients were randomized by strata to treatment or placebo.

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Duration of Follow-up	Interventions Described	Outcomes Assessed	Results
O'Connor, 1999 ¹⁵¹	6 months	Children weighing < 15 kg: 1000 mg DMSA t.i.d. for 5 days followed by 100 mg bid for 14 days; Children weighing > 15 kg: 200 mg tid for 5 days, followed by 200 mg bid for 14 days	Blood lead level	DMSA group: Baseline 34.9 ± 4.7 ug/dl, 1 month 27.4 ± 7.5 ug/dl, 6 months 28.8 ± 6.4 ug/dl; Placebo baseline 33.0 ± 6.2 ug/dl, 1 month 33.2 ± 10.3 ug/dl, 6 months 25.1 ± 6.8 ug/dl (p=0.06). Differences in blood lead level between groups were not statistically significant (p = 0.16 at 1 month, p = 0.06 at 6 months)
Peterson, 2004 ¹⁴¹	34 months	DMSA treatment lasting 26 days, dose based on body surface area; treatment repeated up to 3 times for persistently elevated blood lead level. Domestic cleaning with HEPA vacuum and damp cloth wiping	Change in height and weight from baseline to 9 month follow up and from b	Difference in mean change in height between DMSA treatment vs Placebo. 0-9 months: -0.27 cm (CI = -.42, -.11), 0-34 months -0.43 cm (CI - 0.77, -0.01).
Rogan, 1998 ¹³⁷	36 months	DMSA treatment lasting 26 days, dose based on body surface area; treatment repeated up to 3 times for persistently elevated blood lead level. Domestic cleaning with HEPA vacuum and damp cloth wiping	Behavioral and psychometric assesments, BPb, and a battery of other biochemical tests.	Description of baseline measurements, group characteristics, study methodology.
Rogan, 2000 ¹⁴⁴	12 months	DMSA treatment lasting 26 days, dose based on body surface area; treatment repeated up to 3 times for persistently elevated blood lead level. Domestic cleaning with HEPA vacuum and damp cloth wiping	Blood lead level, ZPP	DMSA-treated group blood lead level 11 ug/dl lower at one week. Rebound began at one week and at 7 weeks DMSA group mean blood lead level was 72% of baseline (placebo group mean blood lead level was 88% of baseline). During the six months after initiation of treatment, the DMSA group had a mean blood lead level 4.5 ug/dl lower than the control group. At 12 months mean DMSA group blood lead level is 2.7 ug/dl lower than the control group, but confidence intervals for overlap At 12 months groups are similar.

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
O'Connor, 1999 ¹⁵¹	ND		Fair
Peterson, 2004 ¹⁴¹	Small, marginally significant decrease in height among treatment group compared to placebo. Excess noted: trauma, scalp rashes, neutropenia/thrombocytopenia, elevated ALT.	Chelation may have adverse effect on growth	Good
Rogan, 1998 ¹³⁷	ND		Good
Rogan, 2000 ¹⁴⁴	No statistically significant difference compared to placebo. Excess noted: trauma, scalp rashes, neutropenia/thrombocytopenia, elevated ALT.	Essentially no effect at 12 months	Good

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Aims	Study Design	Type of Intervention	N	
Rogan, 2001 ¹³⁸	To determine whether treatment of blood lead level < 45 ug/dl with chelation improves cognitive outcomes (TLC trial)	Randomized multicenter, placebo controlled, double-blind trial	Chelation with DMSA after domestic cleaning with HEPA vacuum and damp cloth wiping	1854 evaluated, 780 randomized	Multicent Cincinnati Newark,
Shannon, 2000 ²⁰⁷	Determine incidence of adverse affects of low doses of penicillamine for treatment of blood lead level < 04 ug/dl.	Retrospective analysis	Chelation with penicillamine	55	Urban CI Boston M

Abbreviations

ALT = Alanine transferase; AST = Aspartate aminotransferase; CBC = Complete blood count; DMSA = Dimercapto = Ethylenediaminetetraacetic acid; EP = Erythrocyte protoporphyrin; HEPA = High efficiency particulate air; MCH = hemoglobin; TLC = Treatment of Lead-Exposed Children study; UA = Urine analysis; WBC = White blood cell count; protoporphyrin

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria
Rogan, 2001 ¹³⁸	Children ages 12-33 months, 77% African-American. Most had poor, single mothers and lived in older, poorly maintained residences.	Housing	20-44 ug/dl	Children ages 12-33 months with blood lead level 20-44 ug/dl on two occasions, living in a residence suitable for lead dust reduction. Recruitment varied by location. Patients were randomized by strata to treatment or placebo.
Shannon, 2000 ²⁰⁷	Children, mean age 37.4 ± 24.6 months	Housing	24 ± 5 ug/dl (range 15-37)	Retrospective analysis of medical records of all children who were prescribed d-PCN by the Lead and Toxicology Clinic (LTC) of Children's Hospital, Boston, in 1996. The LTC treatment program receives approximately 1200 annual visits, and works in cooperation with the Massachusetts Childhood Lead Poisoning Prevention Program.

Abbreviations

ALT = Alanine transferase; AST = Aspartate aminotransferase; CBC = Complete blood count; DMSA = Dimercaptosuccinic acid; EDTA = Ethylenediaminetetraacetic acid; EP = Erythrocyte protoporphyrin; HEPA = High efficiency particulate air; MCH = Mean corpuscular hemoglobin; TLC = Treatment of Lead-Exposed Children study; UA = Urine analysis; WBC = White blood cell count; ZPP = Zinc protoporphyrin

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Duration of Follow-up	Interventions Described	Outcomes Assessed	Results
Rogan, 2001 ¹³⁸	36 months	DMSA treatment lasting 26 days, dose based on body surface area; treatment repeated up to 3 times for persistently elevated blood lead level. Domestic cleaning with HEPA vacuum and damp cloth wiping	Scores on developmental, neuropsychological, and behavioral tests (Bayley Scales of Infant Development II, Wechsler Preschool and Primary Scales of Intelligence-Revised, Developmental Neuropsychological Assessment, Connors' Parent Rating Scale-Revised)	First six months: succimer treatment mean blood lead level 4.5 ug/dl lower than placebo. At 36 months, DMSA group scored on average 1 IQ point lower than the control group, and had slightly worse behavior by parental rating compared to the placebo group. The placebo group fared slightly better on a developmental neuropsychological battery of tests. But overall, there was no statistically significant difference between the two groups.
Shannon, 2000 ²⁰⁷	Convenience sample, children who received penicillamine in 1996	Penicillamine at 15 mg/kg/d administered until blood lead level declined and remained < 15 ug/dl, mean duration of treatment was 77 ± 44 days	Blood lead level, CBC, EP, UA	Mean total white blood cell count fell from 8270 ± 2630/mm ³ to 7020 ± 1940/mm ³ (p =0.009) during treatment, post-treatment WBC was not significantly different than pre-treatment WBC. Mean platelet count fell from 364000 ± 117000 /mm ³ to 308000 ± 74000/mm ³ during treatment (p<0.001) and was 338000±74000/mm ³ after chelation (p=0.02). Rash occurred in 4.5% (N=3) of patients. No cases of abnormal urinalysis.

Abbreviations

ALT = Alanine transferase; AST = Aspartate aminotransferase; CBC = Complete blood count; DMSA = Dimercaptosuccinic acid; EDTA = Ethylenediaminetetraacetic acid; EP = Erythrocyte protoporphyrin; HEPA = High efficiency particulate air; MCH = Mean corpuscular hemoglobin; TLC = Treatment of Lead-Exposed Children study; UA = Urine analysis; WBC = White blood cell count; ZPP = Zinc protoporphyrin

TABLE 1. EFFECTS OF CHELATION ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Rogan, 2001 ¹³⁸	No statistically significant difference compared to placebo. Excess noted: trauma, scalp rashes, neutropenia/thrombocytopenia, elevated ALT.	Conclusion: chelation < 45 ug/dl not effective	Good
Shannon, 2000 ²⁰⁷	Rash, depressed WBC and platelet counts.	When compared to results of their previous investigation involving a higher dose, the results suggest that penicillamine at 15mg/kg/d is safer than a higher dose regimen without a significant loss of efficacy.	Case series; non-controlled study.

Abbreviations

ALT = Alanine transferase; AST = Aspartate aminotransferase; CBC = Complete blood count; DMSA = Dimercaptosuccinic acid; EDTA = Ethylenediaminetetraacetic acid; EP = Erythrocyte protoporphyrin; HEPA = High efficiency particulate air; MCH = Mean corpuscular hemoglobin; TLC = Treatment of Lead-Exposed Children study; UA = Urine analysis; WBC = White blood cell count; ZPP = Zinc protoporphyrin

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N	
Aschengrau, 1994 ¹⁸² ; Aschengrau, 1997 ¹⁸³	The impact of soil lead abatement on urban children's blood lead levels: Phase II results from the Boston lead-in-soil demonstration project; Residential lead-based paint hazard remediation and soil lead abatement: their impact among children with mildly elevated blood lead levels	To study the impact of urban soil lead abatement on children's blood lead levels (The Boston Lead-In-Soil Demonstration Project, 1989-1990); To report the Phase II results of the Boston Lead-in-Soil Demonstration Project, which was designed to assess children's blood lead levels and household dust lead levels following (1) lead-based-paint hazard and remediation alone and (2) in combination with soil abatement.	Randomized environmental intervention; no untreated comparison group	Soil	152	B n w ir p

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Aschengrau, 1994 ¹⁸² ; Aschengrau, 1997 ¹⁸³	Children age <4	Soil	7 to 24 ug/dL	Children were eligible if they lived in the neighborhoods of Boston with a high incidence of lead poisoning, were under 4 years of age, and had a finger stick blood lead level from 10-20 ug/dL. Children up to age 4 living on the same premises were also eligible. Also: 1) the amount of peeling paint was less than 30% of exterior walls of the house or 40% of the exterior walls of adjacent buildings; 2) the child's house had a yard at least 10 square feet in size that was composed, at least partly, of accessible soil and/or grass; 3) the surface soil lead levels, 1m from the house, averaged at least 1500 ppm; 4) the house had 8 or fewer apartments; 5) the child was mobile and had never been lead poisoned; and 6) the family lived on the premises for at least 3 months and had no plans to move in the near future.	2 years

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Aschengrau, 1994 ¹⁸² ; Aschengrau, 1997 ¹⁸³	<p>Phase I, 1989-1990: Study group (n=54) received soil and interior dust abatement and loose paint stabilization Comparison group A (n=51) received received interior dust abatement and loose paint stabilization, and Comparison Group B received only loose paint stabilization.</p> <p>Phase II, 1990-1991: Soil abatement was conducted in Comparison Groups A and B, and residential lead-based paint removal was offered to all three groups.</p> <p>Soil abatement: removed 6 inches of top soil from entire yard. Interior dust abatement: vacuuming walls, woodwork, floors, and rugs with a HEPA filter vacuum, and wiping surfaces with wet cloths and furniture with oil-treated cloths Lead-based paint remediation: licensed contractors performed the remediation on exterior and interior areas, using containment barriers and HEPA vacuum units. Surfaces were then wet washed and wood floors were coated with polyurethane.</p>	<p>Three venous blood smples were taken over a 2-year period. During Phase I, samples were obtained before and 10 months after soil or paint abatement. During Phase II, follow-up sampling took place 9 months after soil or paint abatement.</p>

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Aschengrau, 1994 ¹⁸² ; Aschengrau, 1997 ¹⁸³	<p>Pre- and post- soil abatement levels (ug/dL) and change before and after (ug/dL, 95% CI):</p> <p>Study group (Phase I, mixed interventions): 13.10, 10.65; -2.44 (-3.32, -1.57)</p> <p>Group A (Phase II): pre 12.94, post 7.69; change -5.25 (-6.51, -3.99)</p> <p>Group B (Phase II): pre 10.54, post 9.15; change -1.30 (-4.03, +1.26)</p> <p>(includes only children in Groups A and B whose homes were not deleaded during phase II)</p> <p>All groups, all phases combined, irrespective of Phase II deleading status: pre 12.66, post 9.77; change -2.89 (-3.64, -2.13)</p> <p>Soil lead reduction of 2060 ppm is associated with a 2.25 to 2.70 ug/dL decline in blood lead levels. Low levels of soil recontamination 1 to 2 years following abatement indicate that the intervention is persistent.</p> <p>Paint hazard remediation alone was associated with a blood lead increase of 6.5 ug/dL (p=0.05)</p> <p>Paint hazard remediation combined with soil abatement was associated with an increase of 0.9 ug/dL (p=0.36)</p> <p>Conclusion: lead-based-paint hazard remediation is not an effective secondary prevention strategy among children with mildly elevated blood lead levels.</p>	ND	Soil abatement effects on blood lead were reported only for selected children in Groups A and B. Group S had mixed interventions.	Not rated; no comparator group

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N	
Aschengrau, 1998 ¹⁶³	The impact of low technology lead hazard reduction activities among children with mildly elevated blood lead levels	To determine the effect of low-technology lead hazard reduction activities on children's blood and household dust lead levels. The purpose of the intervention was to reduce children's exposure to household lead hazards by removing lead-contaminated dust and loose paint chips from the window and floor areas and by instructing caregivers to maintain clean window and floor surfaces over the follow-up period.	RCT	Dust	63	B
Campbell, 2003 ¹⁶⁷	Effect of a follow-up professional home cleaning on serial dust and blood lead levels of urban children	To determine the effects of a follow-up professional lead dust cleaning of their homes 18 months after an initial cleaning and commencement of therapy.	Non-randomized trial; followup of chelation RCT (TLC)	Dust	73	T L C r d ir

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Aschengrau, 1998 ¹⁶³	Children age <=4	lead-based paint in home	16.9 ug/dL	Eligible children: 1) resided in the city of Boston, 2) were age <=4, 3) had a venous blood lead level from 11 to 24 ug/dL, 4) had no history of lead poisoning (venous lead >=25 ug/dL) or chelation therapy, 5) were not expected to undergo chelation treatment, 6) lived on the premises for at least 3 months with no definite plans to move within the next 3 months, 7) lived in home with lead-based paint in at least two window sills and/or window wells, as determined by sodium sulfide tests, 8) the home had not been previously delead or received lead hazard reduction activities, 9) the parents spoke English, Spanish, or Cape Verdean creole, and 10) no other child in the home was already a study participant.	6 months
Campbell, 2003 ¹⁶⁷	Toddlers aged 12-34 month at enrollment	lead-based paint in home	20-44 ug/dL	780 toddlers with BLLs 20-44 ug/dL enrolled in RCT (TLC study) comparing chelation therapy and placebo. The original study was conducted in Newark NJ, Baltimore MD, Cincinnati OH, and Philadelphia PA. In this study, the 165 study families in Philadelphia were offered a second professional lead dust cleaning of their home, at the 18-month follow-up visit after initiation of treatment.	9 months (from 15 to 24 months posttreatment, with the 2nd cleaning occurring after 18 and before 21 months)

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Aschengrau, 1998 ¹⁶³	<p>Children were screened 1993-1995. Children with severe lead hazards were automatically assigned to an intervention group. Severe hazards were one of the following: 1) paint chips on any floors, 2) severe amounts of loose dust or paint chips in any window well, or 3) holes in walls larger than 1 inch in diameter and positive for lead paint. Children whose homes had lesser hazards were randomly assigned to the intervention group or control group.</p> <p>A one-time intervention was performed by a trained staff member of the Boston Lead Poisoning Prevention Program:</p> <ol style="list-style-type: none"> 1) HEPA-vacuuming all window well, window sill, and floor surfaces; 2) washing window well and window sill surfaces with a trisodium phosphate (TSP) and water solution; 3) repainting window well and window sill surfaces with primer to seal any chipped or flaking paint; and 4) repairing holes in walls. 	<p>Venous samples were obtained to determine blood lead levels at baseline and an average of 6 months after the intervention. Environmental measurements were made of dust, soil, water, and paint.</p>
Campbell, 2003 ¹⁶⁷	<p>As part of the RCT treatment protocol, the children's homes were professionally cleaned to minimize dust lead exposure. After completion of the treatment phase of the TLC trial, 165 families were offered a second professional dust cleaning of their home. 73 self-selected families participated in the second home cleaning 18 months after the initial cleaning and commencement of therapy.</p>	<p>For this analysis, venous blood samples from 15-mo, 18-mo (just prior to the second cleaning), 21-mo, and 24-mo clinical follow-up visits, from 73 children with homes cleaned and 86 children with homes not cleaned.</p>

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Aschengrau, 1998 ¹⁶³	<p>Blood level before & after intervention; mean change (ug/dL):</p> <p>Automatic intervention group (high risk): 17.5, 9.1; -8.4</p> <p>Randomized intervention group: 17.6, 11.5; -6.2</p> <p>Randomized control group: 16.3, 10.4; -5.9</p> <p>Difference between mean changes (95% CI), randomized intervention vs control group: -0.3 (-3.8, +3.3)</p> <p>Automatic intervention vs comparison group -2.5 (-7.0, +2.1)</p>	ND		Fair
Campbell, 2003 ¹⁶⁷	<p>There was no significant difference in GM blood lead levels at any clinic visit between children whose homes were cleaned and those whose homes were not cleaned.</p> <p>Geometric mean BLLs, adjusted for month and child, declined monotonically among 73 children whose homes were cleaned a 2nd time. BLLs of the 86 children whose homes did not receive a 2nd cleaning also declined over time, although there was an unexplained increase at the 3-mo postcleaning follow-up visit.</p> <p>BLLs before the cleaning were higher among children in high-exposure homes (GM 18.1 ug/dL), compared with those in low-exposure homes (GM 14.5 ug/dL). Stratified by randomized treatment, there were only small differences in BLLs: 18.3 ug/dL and 17.1 ug/dL for children in chelation vs. placebo, in high exposure homes; and 14.5 vs 13.5 ug/dL for chelation vs placebo, in low-exposure homes.</p>	ND	Does not report the distribution of chelation vs placebo treatment among children who did or did not receive the 2nd home cleaning.	Fair

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N	
Clark, 2004 ¹⁶⁰	Occurrence and determinants of increases in blood lead levels in children shortly after lead hazard control activities	To examine the effect of lead hazard control strategies on children's blood lead levels immediately after an intervention by the US Department of Housing and Urban Development's (HUD) Lead-Based Paint Hazard Control Grant Program	Cohort study	Lead-based paint and dust hazard control program and survey	869 children	U H U D L H C
Farrell, 1998 ¹⁷⁵	Soil lead abatement and children's blood lead levels in an urban setting	To assess the effect of soil lead abatement (1990) among Baltimore children.	RCT	Soil	Enrolled 408 children in 263 houses; 187 completed the study	2 n B
Galke, 2001 ¹⁷⁰	Evaluation of the HUD lead hazard control grant program: early overall findings	To examine the range of interventions used by grant recipients and assess the effectiveness of the HUD Lead Hazard Control Grant Program (1993-1994), based on blood and dust lead data aggregated across the various interventions.	Descriptive study, no comparison group	Dust	240 children 1212 dwellings	1 d s

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Clark, 2004 ¹⁶⁰	14 state and local governments included in program	Paint, dust, water, soil, home repair/ remodeling	ND	State or local government's participation in HUD's hazard control program	6 weeks
Farrell, 1998 ¹⁷⁵	Children aged 6 months to 6 years	Paint, soil	Baseline venous level: 11 ug/dL 54% of properties had soil samples >1000 ppm.	Subjects were aged 6 months to 6 years, and had been living in the same house (in the selected neighborhoods) for at least 3 months and the family was not planning to move.	1 year
Galke, 2001 ¹⁷⁰	Children aged 6 months to 6 years	Half of dwellings were built before 1910	Median 10 (range 2-48) ug/dL	HUD grantees were required to participated in the evaluation, and also attempted to recruit families residing in the dwellings. Children between age 6 months and 6 years were eligible.	12 months

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Clark, 2004 ¹⁶⁰	Measures blood levels, paint lead levels, dust levels, and parent fills out survey questionnaire (eg: child's age, sex, mouthing behavior, household size, education, etc. Also asked why parents thought that those with ≥ 5 ug/dL increase occurred) (see Appendix for very specific details of these interventions). Intervention strategies categorized as interior, exterior, and site.	Blood tests performed at baseline (within 6 weeks of intervention), immediately after intervention, and later???. On children between 6 months and 6 years old. Some data was included from medical records. Capillary and venous sampling. Paint lead determined pre and post intervention using portable x-ray fluorescence analyzers (XRF) at preintervention on about 100 surfaces per dwelling.
Farrell, 1998 ¹⁷⁵	In summer and fall 1990, loose paint was wet scraped and then cleaned up with a HEPA vacuum. Surfaces were primed and painted twice with latex paint. Strict containment was practiced during the procedure. Contaminated soil at residences (>500 ppm) was replaced with clean soil. At 90% of the properties, all soil was abated. To prevent soil recontamination, exterior paint was stabilized in both the study and control areas before soil abatement. Children's blood lead levels were characterized before and at 3 months and at 1 year after soil abatement. Controls received no treatment.	Children's venous blood levels before and after soil abatement.
Galke, 2001 ¹⁷⁰	Data collection began in 1994. The last dwelling unit was treated in 1997, and the last 12-month data were collected in October 1998. Interior treatment levels were defined by category: spot painting/cleaning, complete painting, painting plus window treatments, painting plus window abatement, full abatement of lead, total dwellings. Each of the 1212 dwellings had interior treatments, while 79% of the dwellings treatments to the exterior of the building, and 14% had soil treatments.	Blood lead levels (venous or capillary) and dust lead loading were gathered prior to the start of lead hazard control work, within 6 weeks after work was completed, 6 months and 12 months after work was completed.

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Clark, 2004 ¹⁶⁰	Of 869 children tested after intervention, 81 (9.%) had blood lead increases of ≥ 5 ug/dL. Increases ranged from 5-25 ug/dL, average increase 8.4 ug/dL. Logistic regression analysis indicated that 4 factors were significantly associated with increases of ≥ 5 ug/dL: 1) child's age at pre-intervention ($p=0.0061$) 2) female caregiver's education ($p=0.002$) 3) general exterior building condition ($p=0.0071$) 4) 2nd season of blood sample collection ($p < 0.001$). As child's age increased, both odds ratio and probability of child showing increase of ≥ 5 ug/dL decreases sharply. In families where the female parent had < high school education, likelihood of ≥ 5 ug/dL was 2.5 times higher than families where female parent had > high school education. As number of exterior deteriorations increased, odds ratio for a ≥ 5 ug/dL was 1.5 higher for 1 deteriorations and 2.3 for 2 or more deteriorations.	ND		Fair
Farrell, 1998 ¹⁷⁵	One year postabatement, blood levels in both groups fell below baseline, but there was no significant effect of soil abatement on children's blood lead. Differences between treatment and control groups were not significant in any of the cross-sectional or longitudinal models. Two years postabatement, soil sampling showed significant lead reaccumulation.	ND		Fair
Galke, 2001 ¹⁷⁰	From preintervention to 12 months postintervention, the geometric mean blood lead level declined from 11.0 to 8.2 (-2.8) ug/dL, a 26% reduction	ND		Not rated; no comparison group

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N
Haynes, 2002 ¹⁶⁵	The effect of interior lead hazard controls on children's blood lead concentrations: a systematic evaluation	To to use meta-analysis of RCTs of low-cost lead hazard control interventions to determine whether low-cost strategies (defined as <\$2500 per housing unit or family) aimed at controlling lead-contaminated dust effectviely prevent childhood lead exposure, as measured by children's blood lead concentration.	Meta-analysis of 4 studies published 1996-2000	Dust; meta-analysis	4 studies, total subjects = 533
Jordan, 2003 ¹⁷⁷	A randomized trial of education to prevent lead burden in children at high risk for lead exposure: efficacy as measured by blood lead monitoring.	Tested blood lead levels every 4 months. Capillary sampling used until age 1, then venous sampling used unless parent objected.	RCT	Education	594 P mothers of n whom 378 N children's blood levels were tested

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Haynes, 2002 ¹⁶⁵	NR	NR	6.7 to 16.9 ug/dL	Eligible articles for meta-analysis: a) randomized allocation of children to either a control group or intervention group; b) low-cost interventions defined as <\$2500; c) blood lead levels used as a measured outcome; and d) trial was not conducted in a community with a continual lead emission source.	6 to 48 months
Jordan, 2003 ¹⁷⁷	Inner-city, economically disadvantaged, ethnically diverse (78% non-Caucasian)	Paint, dust, water, soil, home repair/ remodeling	Before intervention, all levels were < 10 ug/dL	Pregnant women and mothers of young infants were recruited from the Phillips Neighborhood, a large, inner-city, economically disadvantaged (71% of young children live in poverty), and ethnically diverse (78% persons of color) community. Participants were recruited via door knocking, posters, flyers, information tables at community events, and via referral from cooperating OB and pediatric clinics serving the neighborhood.	2 years

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Haynes, 2002 ¹⁶⁵	Three studies included parental education, two studies provided the families with cleaning supplies or equipment, two provided professional cleaning and one made minor housing repairs.	Blood lead levels at baseline and after intervention, comparing intervention and control groups
Jordan, 2003 ¹⁷⁷	Mothers randomly assigned to control or intervention. Intervention offered 20 biweekly in-home educational sessions by same-ethnicity peer educators over a one year period, and quarterly sessions for 2 years following. Sessions included information on lead sources, health consequences, and strategies to reduce exposure.	Tested blood lead levels every 4 months. Capillary sampling used until age 1, then venous sampling used unless parent objected.

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Haynes, 2002 ¹⁶⁵	The weighted mean change in blood lead in all studies was -0.62 ug/dL (95% CI -1.55 to 0.32). No significant difference between the intervention and control groups for either the educational dust control trials (-0.33 ug/dL, 95% CI -1.4 to 0.74) or the professional dust control trials (-1.52 ug/dL, 95% CI -3.41 to 0.37). Intervention and Control Groups were similar in the % of children ≥ 10 ug/dL, but there were significantly fewer children with ≥ 15 ug/dL and ≥ 20 ug/dL in the treatment group than the control group: 6 vs 14% ($p=0.008$), and 2 vs 6% ($p=0.024$) respectively.	ND	Author's conclusion: although low-cost, interior lead hazard control was associated with 50% or greater reduction in the proportion of children who had blood lead concentrations exceeding 15 ug/dL and 20 ug/dL, there was no substantial effect on mean blood lead concentration.	Good
Jordan, 2003 ¹⁷⁷	A greater percentage of children in intervention group (81%) maintained levels < 10 ug/dL, compared with the control group (73%), although the effect was of borderline significance ($p=0.08$). 15% of intervention group and 24% of control group had levels between 10-19.99 ug/dL (ns). 4% of intervention group and 2% of control group had levels > 20 ug/dL (ns). Statistical models show that intervention reduced risk of blood lead ≥ 10 ug/dL by approximately 34% ("borderline significance"). >90% completed 19 or 20 sessions. 50% completed 1st year of followup sessions; <5% completed 2nd year of followup sessions.	ND	Received cash incentives for participation. Possible confounder of mother's education level that was adjusted for. Authors say education alone is not sufficient to lower exposure.	Fair

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N	
Lanphear, 1999 ¹⁷⁸ ; Lanphear, 2000 ⁵⁹ ; Lanphear, 2002 ¹⁹⁵	Primary prevention of childhood lead exposure: a randomized trial of dust control; Long-term effect of dust control on blood lead concentrations; Environmental lead exposure during early childhood	To assess the effectiveness of a dust control education intervention in preventing children's exposure to lead, as measured by blood lead levels up to 24 months and at 48 months. Interviews were conducted to estimate nutritional, behavioral, and demographic factors linked with lead exposure.	RCT	Education	275	C S R Y
Lanphear, 2003 ¹⁸⁴	The effect of soil abatement on blood lead levels in children living near a former smelting and milling operation	To determine the effect of soil abatement for residential soil with mean soil lead concentrations >500 ppm ug/g on blood lead levels in children aged 6-72 months	Two cross-sectional surveys before and after soil abatement	Soil	198 in 1st survey; 215 in 2nd survey	P

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Lanphear, 1999 ¹⁷⁸ ; Lanphear, 2000 ⁵⁹ ; Lanphear, 2002 ¹⁹⁵	Children aged 6 months	NR	2.9 ug/dL (95% CI 2.7-3.1) at age 6 months	Children and their families were eligible if: they lived in Rochester, NY; they denied having plans to relocate in the next 3 months; and they were between ages 5 to 7 months at the baseline visit. Participants were identified and recruited by using sequential lists of live births from three urban hospitals.	48 months
Lanphear, 2003 ¹⁸⁴	Children	Midvale is a former site of a smelting and milling operation	Baseline mean in children with soil >500 ppm: 5.6 ug/dL, with 11% >=10 ug/dL Baseline mean in children with soil <500 ppm: 3.0 ug/dL, with 3% >=10 ug/dL	Children aged 6-72 months who lived in Midvale, Utah for at least 2 months; excluded children who had taken a prescribed iron supplement in the past 2 months or if there had been a major renovation of their residence during the past 12 months.	N/A

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Lanphear, 1999 ¹⁷⁸ ; Lanphear, 2000 ⁵⁹ ; Lanphear, 2002 ¹⁹⁵	After baseline sampling, families were randomly assigned to an intervention group or a control group. Intervention families received up to 8 visits by a dust control advisor, cleaning equipment and supplies, a detergent containing trisodium phosphate. Control families did not receive any education or interventions. (Calendar years of intervention not reported)	Venous blood lead levels measured at baseline (age 6 months), and at ages 12, 8, and 24, 36, and 48 months of age.
Lanphear, 2003 ¹⁸⁴	Soil abatement occurred from 1993 to 1996 as follows: a clay cap was constructed over the tailings at the former mining and milling site adjacent to Midvale; yards with soil lead 500 ppm were excavated to 18 inches and backfilled with clean soil.	Surveys in 1989 and 1998 collected venous blood samples from eligible children, and environmental samples from each residence (dust, paint, soil, water). Intervention group consisted of children whose yards (>500 ppm) were treated; control group were children whose yards (<500 ppm) were not treated.

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Lanphear, 1999 ¹⁷⁸ ; Lanphear, 2000 ⁵⁹ ; Lanphear, 2002 ¹⁹⁵	<p>There was no significant difference in blood lead levels by intervention status at 24 months or 48 months. The geometric mean blood lead levels at 24 months of age in the intervention and control groups were 7.3 ug/dL (95% CI 6.6, 8.2) and 7.8 ug/dL (CI 6.9, 8.7) respectively. At 48 months the g.means were 5.9 ug/dL (95% CI 5.3, 6.7) and 6.1 ug/dL (95% CI 5.5, 6.9)</p> <p>There was no significant effect of the intervention on the mean increase in blood lead levels from 6 to 24 months of age (+5.6 ug/dL in the intervention group vs +6.3 ug/dL in the control group p=0.42).</p> <p>Dust lead levels declined sharply in both the treatment and control groups. There was no significant difference in dust lead levels at 24 months by group, nor a difference in change in dust lead levels from 6 to 24 months by group.</p> <p>Other results (Lanphear, 2002): Dietary iron intake, but not calcium intake, was inversely associated with blood lead levels (p<0.05). Blood lead concentration was over 50% higher in black than in white children (p=0.0001).</p>	ND	Author's conclusion: dust control through education is not effective in the primary prevention of childhood lead exposure	Fair
Lanphear, 2003 ¹⁸⁴	<p>Change in blood lead (ug/dL) before and after soil abatement: Intervention group: 5.6 to 3.0 (-3.6), p=0.0001 Control group: 3.0 to 2.6 (-1.4), p=0.06</p> <p>Stratifying by age, adjusting for mouthing behavior score and socioeconomic status: Age 36-72 months: 2.3 ug/dL decline (p=ns) Age 6-36 months: 2.5 ug/dL decline (p=0.03)</p>	ND	Soil abatement was associated with a significantly greater reduction in blood lead levels than expected among children ages 6-36 months who had not been exposed to lead-contaminated yards in early childhood. A significant reduction was not seen in children aged 36-72 months.	Not rated: not a true cohort study - different children in cross-sectional surveys before & after soil abatement

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N	
Leighton, 2003 ¹⁶⁴	The effect of lead-based paint hazard remediation on blood lead levels of lead poisoned children in New York City	To examine the effects of lead hazard remediation and its timing on the blood lead levels of lead-poisoned children.	Retrospective cohort study	Lead paint hazard remediation	221	N b d 1 D
Rhoads, 1999 ¹⁶¹	The effect of dust lead control on blood lead in toddlers: a randomized trial	To evaluate the effect of an intervention consisting of maternal education and household dust control measures on blood lead in young children at risk of excessive lead exposure	RCT	Dust	113 enrolled; final blood levels obtained from 99	N h

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Leighton, 2003 ¹⁶⁴	Lead-poisoned children	Paint, dust, water, soil, home repair/remodeling	20-44 ug/dL	Identified with levels between 20-44 ug/dL in New York City's blood lead registry; had follow-up blood lead test between 10-14 months after initial test; had lead-based paint hazard identified in primary dwelling unit prior to 10-14 month follow-up; only resided at address with hazard; and were not chelated.	10-14 months
Rhoads, 1999 ¹⁶¹	Mean age of child: 1.7	Dust	Baseline mean, ug/dL: Intervention: 12.4 (SD 5.7) Control 11.6 (SD 6.2)	Families were recruited by posters and door hangers, or referred by municipal lead program, health care providers, or word of mouth. Those with a child aged 6 months to 3 years were eligible. Homes were evaluated for lead paint. The child's mother had to speak Spanish or English to be eligible. Families were excluded if 1) no lead paint was found in the home, 2) the home was in such structural disrepair or was so disorganized that it could not be cleaned effectively, 3) there was evidence of illicit drug use, firearms, or other major staff safety concerns, 4) the child was in regular day care, 5) the family was not interested in participating, or 6) the family could not be recontacted or refused to allow a baseline blood lead sample to be drawn.	1 year

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Leighton, 2003 ¹⁶⁴	<p>Compared blood levels from baseline to 10-14 month follow-up in homes with remediation and homes without remediation during the follow-up period.</p> <p>To investigate timing effect of remediation, children were classified into 3 groups depending on time of diagnosis and date of time of remediation as follows: < 3 months, ≥3 - ≤6 months, > 6 months.</p> <p>Assessed interior components in houses of children < 18 years old identified with blood leadl level ≥ 20 ug/dL.</p>	<p>Blood lead levels tested at baseline and followup. Interior dwellings tested using x-ray fluorescence (XRF) analyzer. Readings ≥ 0.7 mg/cm² classified as positive and in violation of New York City's Health Code.</p>
Rhoads, 1999 ¹⁶¹	<p>Consenting families were randomly assigned to a lead exposure reduction group (n=56) or to an accident prevention control group (n=57). Families in the lead intervention were asked to cooperate with a cleaning program in which two study staff members visited every 2 weeks to clean up potentially lead-contaminated dust. These visits typically lasted 2 hours. Floors and carpets were vacuumed with a HEPA vacuum cleaner, and walls, horizontal surfaces, and uncarpeted areas of floor were wet-wiped or mopped with a low-phosphate detergent solution.</p> <p>Controls were informed about identified lead paint hazards in their homes and received routine information about lead exposure at the time of enrollment. Controls were given home safety items such as fire extinguishers, smoke detectors, safety latches for cupboards, and first aid kits. They did not receive biweekly visits.</p> <p>Caretakers in both groups were invited to attend 4 to 5 educational sessions during the 1-year intervention</p>	<p>Initial and and final blood lead levels (after 1 year); baseline and % decline in sill lead loading</p>

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Leighton, 2003 ¹⁶⁴	<p>Regardless of remediation, mean blood levels declined significantly from 24.3 ug/dL at initial diagnosis to 12.3 ug/dL at follow-up, 50% decline (p<0.01). For 146 children whose homes were remediated, mean blood lead levels declined 53% compared with 41% for the 75 children whose homes were not remediated by the follow-up, a remediation effect of approximately 20% (p<0.01). After adjusting for confounders, remediation effect was 11% (ns). Race was the only factor that confounded the relationship. African American children had higher lead levels in follow-up after remediation. White and Asian children has an adjusted mean follow-up blood lead level that was 30% lower than African American children (p<0.01).Effect of remediation appeared to be stronger in younger children (10 - <36 months) than in older children (36-72 months) (p=0.06). Timing of remediation did not have a significant effect on blood lead levels.</p>	ND	<p>Modest decline in remediation versus no remediation groups. Both group's mean blood lead levels decline. Authors think it is due to aging.</p>	Fair
Rhoads, 1999 ¹⁶¹	<p>Children's blood lead levels (ug/dL) at baseline / follow-up / change / % change Intervention: pre 12.4 / post 10.3 / change -2.1 / -17% Control: pre 11.6 / post 11.6 / change +0.1 / +1% Adjustment for baseline blood lead in a regression model provided an estimated intervention effect of 1.9 ug/dL (p<0.05).</p>	ND		Fair
	<p>Mother's final knowledge score was not a highly significant predictor of blood lead change, adjusted for initial blood lead (p<0.01) and number of cleanings (p<0.01). The contribution of the educational intervention could not be clearly distinguished from the effects of cleaning.</p>			

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N	
Schultz, 1999 ¹⁷⁹	A retrospective examination of in-home educational visits to reduce childhood lead levels.	To examine the changes in blood lead levels of children receiving an in-house education visit and those not receiving an educational visit.	Retrospective cohort study, with reference group	Education	187	M V D re
Strauss, 2005 ¹⁷¹	Evaluation of lead hazard control treatments in four Massachusetts communities through analysis of blood-lead surveillance data	1) To determine whether there are significant differences between dwellings treated under the HUD program and similar untreated dwellings by comparing preintervention to postintervention changes in the distribution of children's BLLs, and 2) to determine whether it is possible to use existing electronic data resources to make such a determination.	Retrospective cohort study, with untreated reference group	Paint	1179	4 H g M B C M S

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Schultz, 1999 ¹⁷⁹	African American, Caucasian, Native American, Asian, other races	Paint, dust, water, soil, home repair/ remodeling	20-24 ug/dL	Identified with levels between 20-24 ug/dL in Milwaukee Health Department records	6 months
Strauss, 2005 ¹⁷¹	Children <=36 months	Paint	Preintervention means (ug/dl) Untreated 4.5 Treated 7.0	Data from 3 sources (local housing programs, local tax assessor offices, and the Massachusetts Childhood Lead Poisoning Prevention Program) was used to identify children that resided in treated and untreated housing units, and their full longitudinal blood-lead history. Children with BLLs > 5 ug/dL before moving into the study housing were excluded. Three sets of matched controls were selected: housing only (based solely upon similar housing characteristics between treated and untreated units), Housing-BLL (selected using a balanced weighting of similar preintervention BLLs and similar housing characteristics), and BLL-Only (selected based upon similar preintervention BLLs, with housing characteristics having relatively little weight). The MA CLPPP provided blood-lead data obtained between 1993 and 2002.	From 1 year pre-intervention to 3 years post-intervention

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Schultz, 1999 ¹⁷⁹	One in-home educational visit lasting about an hour by a Milwaukee Health Department paraprofessional. Visit stressed importance of reducing lead exposure, nutritional suggestions, and dust clean-up practices, and behavioral changes that can reduce lead exposure.	Blood lead levels tested at baseline and 6 months by capillary and venous sampling.
Strauss, 2005 ¹⁷¹	<p>Varied by region:</p> <p>Boston & Cambridge: interior treatments included cleaning, complete stabilization, floor treatments, window replacements, and wall enclosure/encapsulation. Exterior treatments included complete paint stabilization plus some enclosure, encapsulation, or removal.</p> <p>Malden, interior: Removing all lead-based paint and enclosing or encapsulating all lead-based paint.</p> <p>Springfield, interior: Removing all lead-based paint on mouthable and movable impacted (both friction and friction and impact) surfaces and loose leaded surfaces.</p> <p>Malden & Springfield, exterior: Enclose, encapsulate or remove all lead-based paint.</p>	Geometric mean BLLs from before and after treatment were compared for the two sets of housing (treated and untreated dwellings). Blood lead levels were tested 1 year pre-intervention, and 1-3 years post-intervention.

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Schultz, 1999 ¹⁷⁹	Intervention group blood lead levels declined by 4.2 micro g/dL or about 21%. Reference group levels declined by 1.2 ug/dL (6%). Intervention group decline was 3.1 ug/dL (15%) greater than the reference group (between groups difference statistically significant, p<0.001).	ND	Cost of educational intervention approximately \$100 per household visit.	Fair
Strauss, 2005 ¹⁷¹	<p>Pre vs. post geometric mean BLLs (% BLL >=10 ug/dL); P-value for change in geometric mean BLL comparing 1 year pre-intervention versus 3 years post, adjusted for time, seasonality, age, and gender, HUD versus untreated:</p> <p>With controls matched on housing criteria only: HUD-treated: 7.04 (42.7%) vs. 3.54 (13.2%) Untreated control: 4.57 (19.7%) vs 3.45 (10.0%) P<0.001</p> <p>With controls matched on a combination of preintervention BLL and housing information: HUD-treated: 7.07 (42.8%) vs. 3.57 (12.5%) Untreated control: 5.76 (29.1%) vs 3.96 (15.9%) P=0.116</p> <p>With controls matched on preintervention BLL information: HUD-treated: 7.07 (42.9%) vs 3.59 (12.6%) Untreated control: 6.62 (36.9%) vs. 4.28 (16.0%) P=0.015</p>	ND	There were fewer children measured postintervention in both treated and untreated homes: 66% and 37% in the analysis matching on preintervention BLL. Per author: Results indicate a 50% decline in BLLs in treated homes, a significantly larger decline than in untreated homes, after adjusting for the general downward trend in BLLS observed in the general population for the last several years.	Fair

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N	
Swindell, 1994 ¹⁶⁸	Home abatement and blood lead changes in children with class III lead poisoning	To study the effect of home abatement on blood lead levels in children from central Massachusetts who had not undergone chelation therapy and whose homes were abated between 1987 and 1990, before and after abatement policies became more stringent in 1988	Retrospective chart review; no comparison group	Paint; dust	132	V c N
Taha, 1999 ¹⁶²	Low-cost household paint abatement to reduce children's blood lead levels	To examine the effectiveness of low-cost lead household paint abatements, which treated deteriorated surfaces instead of the entire house, on the blood lead levels of young, urban children: an evaluation of environmental and educational interventions in 1994.	Retrospective cohort study	Paint; dust	42 eligible; N data analyzed for 37	N

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Swindell, 1994 ¹⁶⁸	Children with high lead levels, mean age 35 months, range 12-91 months 52% boys	Lead paint shed from deteriorating surfaces	Preabatement level = 26.0 (+- 6.5) ug/dL	Massachusetts Dept of Public Health records were reviewed of all children from central MA with confirmed venous blood lead levels >=25 ug/dL from 1987 through 1990. Eligibility criteria: 1) the child's principal dwelling must have been abated during they years 1987-1990; 2) the child must have had at least one venous blood lead determination within 6 months prior to the abatement; 3) the child must have had at least one venous blood lead determination 2 weeks to 6 months following abatement; 4) the child must not have received chelation therapy during that time period; and 5) the child must have lived in the same dwelling throughout the study period.	2 weeks to 6 months following abatement
Taha, 1999 ¹⁶²	Intervention: 86.4% aged 1-3 64.9% male 75.7% black 5.4% white Control: 63.1% aged 1-3 41.5% male 92.3% black 4.6% white	household paint	28.8 ug/dL	Milwaukee households that met the following criteria: 1) a child between the ages of 6 months and 6 years was a resident during initial and folow-up blood lead tests, 2) the child's initial blood lead level was between 25 and 44 ug/dL inclusive and the child was not chelated, 3) a low-cost abatement was performed, and 4) the child had a follow-up blood lead taken at least 28 days after the abatement was completed. Controls: 65 children selected retrospectively from the Milwaukee Health Department who resided in the same area as the intervention children per zip code, were aged 6 months to 6 years, lived in the same unabated home in 1994 during which 2 blood lead tests were taken, and had an initial blood lead of 25-44 ug/dL with a follow-up blood lead taken at least 28 days later.	Mean 69 days after abatement

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Swindell, 1994 ¹⁶⁸	Abatement policies in Massachusetts from 1987-1990. In 1988, there were no regulations regarding the abatement process itself: paint removal could occur by sanding, scraping, or torching, with no formal dust-control methods or clean procedures mandated. Since 1988, more stringent regulations were enacted to control dust exposure from abatement.	Venous blood lead levels measured 2 weeks to 6 months following abatement.
Taha, 1999 ¹⁶²	<p>Education: A public health nurse visited the household and educated the family about lead poisoning and risk reduction activities that would protect the child, such as advising on nutrition, frequent handwashing, and strict cleaning procedures to reduce dust and paint chips.</p> <p>Environmental: An inspector conducted a risk assessment. Necessary treatments to deteriorated painted surfaces were performed by a certified lead abatement contractor. All households had chipping, deteriorating, flaking, or peeling lead paint. Deteriorated window wells were enclosed with aluminum or vinyl. other painted surfaces were wet-scraped and repainted with latex paint.</p>	The analysis used 1990-1994 data on 13,476 children to perform statistical adjustment for seasonal fluctuations.

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Swindell, 1994 ¹⁶⁸	<p>Mean blood lead levels changed from 26.0 ug/dL at baseline to 21.2 ug/dL (p<0.001).</p> <p>The % of children with reduced blood lead levels varied with baseline blood lead levels. 97% of children with baseline blood lead levels >=30 ug/dL had reductions within 1 year; 81% of those with baseline blood lead levels from 20-29 ug/dL had reductions, but only 35% of subjects with baseline blood lead levels <20 ug/dL had decreases. In this group, mean blood lead levels increased following abatement, from 16.7 to 19.2 ug/dL (p=0.053)</p> <p>There was no meaningful change in pre- to postabatement levels by calendar year of abatement.</p>	ND	<p>The effect of intervention was absent in children with initial blood lead levels of less than 20 ug/dL.</p> <p>No control group.</p>	<p>Not rated; no comparison group</p>
Taha, 1999 ¹⁶²	<p>Initial unadjusted mean blood lead level was 31.8 ug/dL. Follow-up blood lead was taken on average 69 days after abatement, and 172 days after the initial sample. After treatment, the average blood lead levels were 24.6 ug/dL, representing a decrease of 6.2 ug/dL or 22%.</p> <p>After adjusting for season and age of child, the average decrease was 6.0 ug/dL, an 18% reduction.</p> <p>Adjusted blood lead levels, ug/dL: initial / follow-up / change / percentage change Intervention children (n=37): 28.8 / 22.8 / -6.0 (p=0.05) / -18.0% Control children (n=65): 31.1 / 29.5 / -1.6 (p=ns) / -1.8%</p>	ND		Fair

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Title	Aims	Study Design	Type of Intervention	N	
Yiin, 2003 ¹⁶⁶ Parent study: Rhoads, 1999 ¹⁶¹	Impact of home carpets on childhood lead intervention study (CLEARS)	To examine the reduction in children's blood lead level achieved in homes with and without substantial carpeting on floors.	RCT	Dust	39	N h

Abbreviations

ND =Failure to describe

NR =Absence

RCT = Randomized controlled trial

SD = Standard deviation

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Population/ Risk Factors	Source of Exposure/ Risk Factors	Lead Levels	Main Eligibility Criteria	Duration of Follow-up
Yiin, 2003 ¹⁶⁶ Parent study: Rhoads, 1999 ¹⁶¹	Children aged 6-36 months	NR	10.61 ug/dL	Children aged 6-36 months enrolled in Childhood Lead Exposure and Assessment Reduction Study (CLEARS).	12 months

Abbreviations

ND =Failure to describe
 NR =Absence
 RCT = Randomized controlled trial
 SD = Standard deviation

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Interventions Described	Outcomes Assessed
Yiin, 2003 ¹⁶⁶ Parent study: Rhoads, 1999 ¹⁶¹	Participating families were randomized to receive intervention or control. Intervention group: offered home cleaning services every 2 weeks over a 12-month period. Control group was assisted with home safety and accident prevention	Wipe and vacuum samples of household dust were obtained, and blood lead specimens were collected, at baseline and again after 12 (+3) months of participation. Families were categorized by carpet status: having carpets in >50% (n=16) vs not (n=23).

Abbreviations

- ND =Failure to describe
- NR =Absence
- RCT = Randomized controlled trial
- SD = Standard deviation

TABLE 2. EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results	Adverse Effects	Comments	Quality Rating
Yiin, 2003 ¹⁶⁶ Parent study: Rhoads, 1999 ¹⁶¹	Mean baseline blood lead level (ug/dL): 10.53 in carpeted group, 10.66 in uncarpeted group Reduction in intervention group: Carpeted: -8% (p=ns), final blood lead level 9.69 ug/dL Uncarpeted: -26% (p=0.004), final blood lead level 7.90 ug/dL The blood lead reductions were linearly related to the number of cleaning visits in the uncarpeted homes (r=0.67, p<0.001), whereas no significant relation was found in the carpeted homes (r=0.04, p=0.885)	ND	Cleaning resulted in a significant reduction in blood lead level in uncarpeted households, but not in carpeted households.	Fair

Abbreviations

- ND =Failure to describe
- NR =Absence
- RCT = Randomized controlled trial
- SD = Standard deviation

TABLE 3. SUMMARY OF EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year (Quality)	Study Design	Type of Intervention	Years con- ducted	N	Age	Duration of Follow-up	Baseline blood lead level
Aschengrau, 1994 ¹⁸² ; Aschengrau, 1997 ¹⁸³ (N/A)	Randomized environmental intervention; no untreated comparison group	Soil	1989-1990	152	<=4	2 years	7 to 24 ug/dL
Aschengrau, 1998 ¹⁶³ (Fair)	RCT	Dust, paint	1993-1995	63	<=4	6 months	16.9 ug/dL
Campbell, 2003 ¹⁶⁷ (Fair)	Non-randomized controlled trial; followup at the Philadelphia site of TLC, a chelation RCT	Dust	NR	73	12-34 months	3-6 months posttreatment	20-44 ug/dL
Clark, 2004 ¹⁶⁰ (N/A)	Observational, no untreated comparison group	Dust, paint	NR	869 children	6 months to 6 years	6 weeks	ND

TABLE 3. SUMMARY OF EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year (Quality)	Blood lead level (ug/dL) by group (Treatment vs. Control): Initial / final / change	Summary of effect (+ indicates benefit)
Aschengrau, 1994 ¹⁸² ; Aschengrau, 1997 ¹⁸³ (N/A)	T1: 13.10 / 10.65 / -2.44 (95% CI -3.32, -1.57) T2: 12.94 / 7.69 / -5.25 (95% CI -6.51, -3.99) T3: 10.54 / 9.15 / -1.30 (95% CI -4.03, +1.26) All Ts combined: 12.66 / 9.77 / -2.89 (95% CI -3.64, -2.13) C: None	N/A
Aschengrau, 1998 ¹⁶³ (Fair)	T1 (high blood lead level, not randomized): 17.5 / 9.1 / -8.4 T2 (rand.): 17.6 / 11.5 / -6.2 C (rand.): 16.3 / 10.4 / -5.9 T1 vs C: -0.3 (95% CI -3.8, +3.3) T2 vs C: -2.5 (95% CI -7.0, +2.1)	No effect
Campbell, 2003 ¹⁶⁷ (Fair)	No significant difference in geo.mean BLLs at any clinic visit between children whose homes were cleaned vs. those whose homes were not cleaned. BLLs declined among both groups.	No effect
Clark, 2004 ¹⁶⁰ (N/A)	Mean change after intervention +8.4 ug/dL Predictors of blood lead level increase of >5 ug/dL: Child's age at baseline (p=0.0061) Mother's education (p=0.002) Exterior building condition (p=0.0071) Season of sample collection (p<0.001)	N/A

TABLE 3. SUMMARY OF EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year (Quality)	Study Design	Type of Intervention	Years conducted	N	Age	Duration of Follow-up	Baseline blood lead level
Farrell, 1998 ¹⁷⁵ (Fair)	RCT	Soil	1990	Enrolled 408 children in 263 houses; 187 completed the study	6 months to 6 years	1 year	11 ug/dL
Galke, 2001 ¹⁷⁰ (N/A)	Descriptive study, no comparison group	Dust	1994-1997	240 children 1212 dwellings	6 months to 6 years	12 months	Median 10 ug/dL
Haynes, 2002 ¹⁶⁵ (Good)	Meta-analysis	Dust, paint; meta-analysis of RCTs	NR	4 studies, total subjects = 533	NR	6 to 48 months	6.7 to 16.9 ug/dL
Jordan, 2003 ¹⁷⁷ (Fair)	RCT	Education	NR	594 mothers of whom 378 children's blood levels were tested	Birth to 36 months	2 years	< 10 ug/dL

TABLE 3. SUMMARY OF EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year (Quality)	Blood lead level (ug/dL) by group (Treatment vs. Control): Initial / final / change	Summary of effect (+ indicates benefit)
Farrell, 1998 ¹⁷⁵ (Fair)	T: 12.1 (1988) / 9.7 (1991) C: 10.9 (1988) / 8.4 (1991) Treatment effect, adjusted for effects of time, seasonality, SES, age, and mouthing behavior T (pre - post): 0.030 (SE 0.034) C (pre - post): 0.075 (SE 0.036) T vs C: -0.045 (SE 0.037)	No effect
Galke, 2001 ¹⁷⁰ (N/A)	T: 11.0 / 8.2 / -2.8 C: none	N/A
Haynes, 2002 ¹⁶⁵ (Good)	Weighted mean change, T vs C (95%CI): 2 educational dust control trials: -0.33 (-1.4, 0.74) 2 professional dust control trials: -1.52 -3.41, 0.37 All trials: % \geq 10 ug/dL in T vs C: similar % \geq 15 ug/dL in T vs C: 6 vs 14% (p=0.008) % \geq 20 ug/dL in T vs C: 2 vs 6% (p=0.024)	No effect overall; tx effects seen at higher lead levels
Jordan, 2003 ¹⁷⁷ (Fair)	T vs C % who maintained blood lead level < 10 ug/dL: 81 vs 73% (p=ns) % with blood lead level 10-19.99: 15 vs 24% (p=ns) % with blood lead level >20 ug/dL: 4 vs 2% (p=ns)	No effect

TABLE 3. SUMMARY OF EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year (Quality)	Study Design	Type of Intervention	Years conducted	N	Age	Duration of Follow-up	Baseline blood lead level
Lanphear, 1999 ¹⁷⁸ ; Lanphear, 2000 ⁵⁹ ; Lanphear, 2002 ¹⁹⁵ (Fair)	RCT	Education	NR	275	6 months at baseline, followed to age 48 months	48 months	2.9 ug/dL
Lanphear, 2003 ¹⁸⁴ (N/A)	Two cross-sectional surveys before and after soil abatement	Soil	1993-1996	198 in 1st survey; 215 in 2nd survey	6-72 months	N/A (cross-sectional)	5.6 ug/dL
Leighton, 2003 ¹⁶⁴ (Good)	Retrospective cohort study	Dust, paint	1994-1997	221	6 months to 6 years	10-14 months	20-44 ug/dL
Rhoads, 1999 ¹⁶¹ (Fair)	RCT	Dust	NR	113; final blood lead level obtained from 99	6 to 36 months	1 year	12 ug/dL
Schultz, 1999 ¹⁷⁹ (Fair)	Retrospective cohort study	Education	1994	187	Mean age 3.35	6 months	20-24 ug/dL

TABLE 3. SUMMARY OF EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year (Quality)	Blood lead level (ug/dL) by group (Treatment vs. Control): Initial / final / change	Summary of effect (+ indicates benefit)
Lanphear, 1999 ¹⁷⁸ ; Lanphear, 2000 ⁵⁹ ; Lanphear, 2002 ¹⁹⁵ (Fair)	Change from age 6 to 24 months: T: 2.8 / 7.3 / +5.6 (sic) C: 2.9 / 7.8 / +6.3 (sic) T vs C: (p=ns)	No effect
Lanphear, 2003 ¹⁸⁴ (N/A)	T: 5.6 / 3.0 / -3.6, p=0.0001 C: 3.0 / 2.6 / -1.4, p=0.06 Stratifying by age, adjusted for mouthing behavior score and socioeconomic status: Age 36-72 months: 2.3 ug/dL decline (p=ns) Age 6-36 months: 2.5 ug/dL decline (p=0.03)	Effect seen only in young children who had not been exposed
Leighton, 2003 ¹⁶⁴ (Good)	Decline occurred regardless of remediation: 24.3 / 12.3 / -12 (p<0.01) T: 24.6 / 11.6 -53% C: 23.8 / 13.9 -41% Remediation effect adjusted for race: 11% (p=ns) Effect of remediation tended to be stronger in younger children (10 to <36 months) vs 36-72 months (p=0.06)	No effect
Rhoads, 1999 ¹⁶¹ (Fair)	T: 12.4 / 10.3 / -2.1 C: 11.6 / 11.6 / +0.1 T vs C: -1.9 ug/dL (p<0.05) Adjustment for baseline blood lead level	+
Schultz, 1999 ¹⁷⁹ (Fair)	Change in blood lead level, T vs C: -4.2 vs -1.2 (p<0.001)	+

TABLE 3. SUMMARY OF EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year (Quality)	Study Design	Type of Intervention	Years conducted	N	Age	Duration of Follow-up	Baseline blood lead level
Strauss, 2005 ¹⁷¹ (Fair)	Retrospective cohort study	Dust, paint	1993-2002	1179	<=36 months	3 years	4.5-7.0 ug/dL
Swindell, 1994 ¹⁶⁸ (N/A)	Retrospective chart review; no comparison group	Dust, paint	1987-1990	132	mean 35 months, range 12-91 months	2 weeks to 6 months following abatement	26 ug/dL
Taha, 1999 ¹⁶² (Fair)	Retrospective cohort study	Dust, paint	1994	42 eligible; data analyzed for 37	6 months and 6 years	Mean 69 days after abatement	28.8 ug/dL
Yiin, 2003 ¹⁶⁶ Parent study: Rhoads, 1999 ¹⁶¹ (Fair)	Observational study, part of RCT (Rhoads, 1999)	Dust, carpeted vs uncarpeted	NR	39	6 to 36 months	12 months	10.61 ug/dL

Abbreviations

N/A=Not applicable; NR=Not reported; RCT=Randomized controlled trial

TABLE 3. SUMMARY OF EFFECTS OF ENVIRONMENTAL MODIFICATIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year (Quality)	Blood lead level (ug/dL) by group (Treatment vs. Control): Initial / final / change	Summary of effect (+ indicates benefit)
Strauss, 2005 ¹⁷¹ (Fair)	Geometric mean BLLs; P-value for treated vs control, adjusted for time, seasonality, age, and gender, Matched on preintervention BLL: T: 7.07 / 3.59 / -3.48 C: 6.62 / 4.28 / -2.34 P = 0.015 Matched on preintervention BLL and housing criteria combined: T: 7.07 / 3.57 / -3.50 C: 5.76 / 3.96 / -1.80 P = 0.116	+
Swindell, 1994 ¹⁶⁸ (N/A)	T: 26.0 / 21.2 / -4.8 (p<0.001) T group with baseline <20 ug/dL: 16.7 / 19.2 / +2.5 (p=0.053) C: none Stratified by baseline blood lead level, reductions within 1 year occurred in 97% with baseline >=30 81% with baseline 20-29 35% with baseline <20	+ only if baseline blood lead level >=20
Taha, 1999 ¹⁶² (Fair)	Adjusted for season and age of child: T: 28.8 / 22.8 / -6.0 (p=0.05) C: 31.1 / 29.5 / -1.6 (p=ns)	+
Yiin, 2003 ¹⁶⁶ Parent study: Rhoads, 1999 ¹⁶¹ (Fair)	Carpeted: 10.53 / 9.69 / -0.84 Uncarpeted: 10.66 / 7.90 / -2.76 Significance wrt # cleaning visits: Carpeted: p=ns Uncarpeted: p<0.001	N/A

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Dalton, 1997 ¹⁸⁵	Calcium Iron Phosphorus	Randomized controlled trial	Infants aged 3.6 - 6 months in Lawrence, MA. High proportion of low income families. Data collected 1991-1993. Majority Latino (> 90%).	103	0.12 micro mol/dL - 0.07 micro mol/dL	Infants randomized to receive iron infant formula (465 mg Ca and 31 P/L) or the same formula with added calcium glycerophosphate (1800 mg and 1390 mg P/L) for 9 months. Iron analyzed every month. Blood samples were taken at baseline, 4 and 9 months to measure BPbs, serum ferritin, total iron binding capacity, erythrocyte protoporphyrin, and hematocrit. Control treatment group was 4 times greater than control group.
Gallicchio, 2002 ¹⁸⁶	Calories Carbohydrates Fat Vitamin C	Prospective cohort study	Children, age 1 (approximately), from low income families, living in urban houses built prior to 1950. 85% African American.	205	mean 4.0 micro g/dL (range 1-19 micro g/dL) 4.9% ≥ 10 micro g/dL	Measured children's venous BPbs and nutritional status including total calcium intake, total fat intake, protein, carbohydrates, saturated fat, monounsaturated fat, polyunsaturated cholesterol, animal fat, vegetable calcium, iron, magnesium, phosphorus, zinc, vitamin D, and vitamin C (using Children's Nutrition Questionnaire designed by Harvard University's Public Health), and amount of lead exposure (from dust samples) with followup measurements after a year.

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Dalton, 1997 ¹⁸⁵	There were no significant differences by treatment group in mean or median change from baseline of serum ferritin, total iron binding capacity, erythrocyte protoporphyrin, or hematocrit at 4 and 9 months after enrollment. Incidence of iron deficiency was similar for both groups and no infant developed iron deficiency anemia during the trial.	ND	Healthy, full term infants fed iron-fortified formula do not need to worry about the inhibitory effect of calcium and phosphorus on iron absorption.	Good
Galicchio, 2002 ¹⁸⁶	Statistically significant positive associations ($p < 0.05$) were found between blood lead and calories, total fat, saturated fat, and monounsaturated fat. Statistically significant negative associations ($p < 0.05$) were found between blood lead and carbohydrates and vitamin C. After multiple linear regression analyses, statistically significant positive associations were found between blood lead and total fat ($p = 0.03$) as well as blood lead and saturated fat ($p = 0.02$), independent of lead exposure and age of the child. Total caloric intake was found to be a marginally significant effect modifier of the association between lead exposure and blood lead ($p = 0.06$).	ND		Fair

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Hammad, 1996 ¹⁸⁷	Iron	Cross-sectional study	Children from 9 months - 5 years old cared for at University of Maryland at Baltimore Pediatric Ambulatory Center. Low income, inner-city families.	299	NA	Nutritional status (using modified, unvalidated for children, but valid for adults, Gladys Block food frequency questionnaire), socioeconomic status, medical history, and potential lead exposure were assessed. Blood samples were evaluated for blood lead (BPb), iron (ferritin), free erythrocyte protoporphyrin, calcium, and heme
Haynes, 2003 ¹⁹⁶	Calcium Iron	Prospective cohort study	Children living in Rochester, NY and were 5-7 months old at baseline visit. Low income families. (same participants in Lanphear, 2002)	275 (245 at 24 month followup; 239 with adequate blood samples)	NA	Assessed BPbs of children at 6 , 12 , and 24 months of age. Nutritional status was also measured at these same timepoints by a trained interviewer using the caretaker questions about child dietary intake using a food frequency checklist (Willet, 1990). Breast milk was incorporated into checklist.

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Hammad, 1996 ¹⁸⁷	Average blood lead was 11.4 micro g/dL. After adjusting for confounders using multiple linear regression models, a negative association between blood lead and dietary iron intake was found (p=0.03). No association was found between blood lead and serum iron.	ND		NA
Haynes, 2003 ¹⁹⁶	Calcium intake was inversely associated with children's blood lead (p=0.03) in a multivariate model that included VDR Fok 1 genotype as an independent variable.	ND	No significant association was observed when the polymorphism was not included (Lanphear BP, et al. Environmental lead exposure during early childhood. Journal of Pediatrics 2002;140:40-47). No significant effect modification of calcium intake on blood lead by genotype was found (p=0.49), therefore interpretation of the results is uncertain.	Fair

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Lanphear, 2002 ¹⁹⁵	Iron Calcium Vitamin C Vitamin D	Prospective cohort study	Children living in Rochester, NY and were 5-7 months old at baseline visit. Low income families. (same participants in Haynes, 2003)	249	2.9 micro-g/dL (95% CI, 2.7-3.1)	Assessed BPbs of children at 6 , and 24 months of age. Nutritional status was also measured at these same timepoints by a trained interviewer. The caretaker questions about child dietary intake using a food frequency checklist (Willett, 1990). Breast milk was incorporated into checklist.
Lee, 2005 ¹²	Calories Fat Thiamine Pyridoxine Vitamin E Ascorbic acid Folate Calcium Phosphorus Iron	Cross-sectional study	Women 20-49 years old from National Health and Nutritional Survey (NHANES III)	4,394 (3,716 had complete data for all variables in study)	NA	NHANES III data retrieved through interviews, questionnaires, and examinations. Survey contained consumption measurements for 1 hour recall) along with dietary, nutritional, and health status measurements.
Lucas, 1996 ¹⁸⁸	Calories Fat	Cross-sectional study	Children ages 9-6 years, cared for at University of Maryland at Baltimore Pediatric Ambulatory Center. Low income, inner-city families.	296	NA	Nutritional status (using modified, unvalidated for children, but validated for adults Gladys Block food frequency questionnaire), socioeconomic status, medical history, and potential sources of lead exposure were assessed. Blood samples were evaluated for BPbs, iron (ferritin), free erythrocyte protoporphyrin, calcium, and heme

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Lanphear, 2002 ¹⁹⁵	At 24 months of age, BPbs were 7.5 micro-g/dL. 82 (33%) had BPb levels \geq 10 micro-g/dL; 32 (13%) has levels \geq 15 micro-g/dL; 14 (6%) had levels \geq 20 micro-g/dL. Dietary iron intake was inversely associated with BPb levels ($p = 0.03$) during the first year of life. Calcium intake was not associated with BPb concentration.	ND	In adjusted analysis, lead-contaminated floor dust, soil, and water contributed to lead intake in first 2 years of life ($p < 0.05$). BPb concentration was $> 50\%$ higher in African American children than Caucasian children.	Good/ Fair
Lee, 2005 ¹²	Average blood lead level of reproductive age woman was 1.78 micro g/dL. Inverse associations ($p < 0.05$) between blood lead level and thiamine and serum folate. Positive associations ($p < 0.05$) between blood lead level and iron, pyridoxine intake, and folate.	ND		NA
Lucas, 1996 ¹⁸⁸	Average blood lead was 11.4 micro g/dL. After adjusting for confounders using multiple linear regression models, significant positive associations with blood lead were found independently for total caloric intake ($p=0.01$) and dietary fat ($p=0.05$).	ND		NA

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Markowitz, 1996 ¹⁵⁷	Iron	Prospective cohort study	Moderately lead poisoned children referred to Montefiore Medical Lead Clinic from 1986-1992 with BPbs 25-55 micro g/dL. Low income, inner-city families, living in pre-1960 housing. 2/3 Hispanic, 1/3 African American.	79	NA	Assessed BPbs repeated over a 6 time period. Mixed interventions (chelation because of negative lead mobilization effects to the chelation including iron therapy for children with ferritin levels < 16 micro g/L.
Markowitz, 2004 ¹⁸⁹	Calcium	Randomized controlled trial	Children ages 1-6 referred to Montefiore Medical Center with BPbs between 10-44 micro g/dL	88	10-44 micro g/dL	1800 mg Ca per day between supplement and diet for treatment group. Stratified children into 2 groups: 1 months and 36-72 months, based on epidemiology of lead absorption. BPbs measured at enrollment, 3 months and 6 months.

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Markowitz, 1996 ¹⁵⁷	BPbs declined 27% on average over 6 months. Two thirds < 25 micro g/dL, 7% < 15 micro g/dL. However, iron status did not account for change in BPb levels.	ND	Mixed interventions. Describes home assessment tool HES (home environmental score).	Fair
Markowitz, 2004 ¹⁸⁹	No significant differences between BPb levels in either group. Ca supplementation of 1800 mg/day for 3 months or 6 months did not reduce BPb levels.	Abdominal pain complaints occurred infrequently in both groups.	BPb boundaries chosen because 10 micro g/dL is current definition of lead poisoning, and BPb \geq 45 micro g/dL required chelation therapy. Also measured hand-to-mouth behavior and dust samples also measured.	Good/ Fair

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Sargent, 1999 ¹⁹⁰	Calcium Iron Phosphorus	RCT	Infants aged 3.6 - 6 months in Lawrence, MA. High proportion of low income families. Data collected 1991-1993. Majority Latino (> 90%).	103; complete lab data collected for 81 (78.6%) of original random assignment	< 25 micro g/dL	Infants randomized to receive iron infant formula (465 mg Ca and 31 P/L) or the same formula with added calcium glycerophosphate (1800 mg Ca and 1390 mg P/L) for 9 months. Infants were assessed monthly for tolerance to formula, adverse effects, and size measurements. Urine samples were analyzed at baseline and 1,2,4,6,9 months to measure excretion of calcium and creatinine. Blood samples were taken at baseline, 4 and 9 months to measure BPbs, serum calcium, serum phosphorus, serum ferritin, total iron binding capacity, erythrocyte protoporphyrin, and hematocrit. Dust and water samples were taken at 1 month after randomization.

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Sargent, 1999 ¹⁹⁰	There was no significant difference between groups in the mean ratio of urinary calcium to creatinine, serum calcium and phosphorus, or change in iron status (serum ferritin, total iron binding capacity). At month 4, the median increase from baseline BPbs in the treatment group was 57% of the increase for the control group (p=0.039), but this effect weakened after month 4 through the final 9th month of the trial. Because the effect did not last, cannot conclude that calcium glycerohosphate supplement prevented lead absorption.	10 children distributed evenly between groups has at least one urine sample with a ratio of urinary calcium to creatinine above the age-related norm. 2 had repeat elevated levels (one in each group). 1 child in the control group had an elevated serum calcium level. 13 children had low serum ferritin concentrations (5 in control and 8 in treatment group).		Good/ Fair

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Schell, 2004 ¹⁹¹	Calcium Ferritin Iron Protein Supplements Vitamin D Zinc	Prospective cohort study	Mother/Infant pairs of low socioeconomic status in Albany County, NY from APILS (Albany pregnancy infancy lead study) 1992-1998	169	1.6 - 10 micro g/dL at birth	Diets assessed at 3 month intervals. 24 hour diet recall reported by primary caregiver. Potential impact of protein, zinc, calcium, vitamin D, fat, serum iron, ferritin at 6 and 12 months of age examined. Nutritional intakes are compared to the 1989 Recommended Dietary Allowances (RDA) amounts. At first 6 months, few were below the amounts for calcium, vitamin D, or iron. 15.4% fell below for protein, 25% for calories, and 37.9% fell below for zinc. At 9 and 12 months, > 20% fell below RDA for calcium, vitamin D, iron, zinc, and two thirds fell below for protein and D.

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Schell, 2004 ¹⁹¹	<p>By 6 months, mean BPbs significantly increased from birth to 2.3 micro g/dL ($p < 0.001$); none were ≥ 10 micro g/dL. By 12 months, mean BPbs significantly increased from 6 months to 5.1 micro g/dL ($p < 0.001$) and 18% were ≥ 10 micro g/dL.</p> <p>Observed significant inverse relationships between infant's 6 month lead level and intake of zinc ($p = 0.003$), iron ($p = 0.015$), and calcium ($p < 0.001$). At 12 months, low iron intake continued to be associated with higher lead levels ($p = 0.041$), although zinc and calcium did not. Protein had a paradoxical effect (associated with lower lead at 6 months ($p = 0.001$), but higher lead at 12 months. Serum vitamin D and ferritin were not associated with lead levels, nor was vitamin supplement use.</p>	ND		Fair

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Schnell, 2003 ¹⁹²	Calcium Ferritin Iron Supplements Vitamin D Zinc	Prospective cohort study	Mother/Infant pairs of low socioeconomic status in Albany County, NY from APILS (Albany pregnancy infancy lead study) 1992-1998	220	1.58 micro g/dL neonates	Maternal BPbs, anthropometry (w arm circumference, triceps skinfol thickness, etc.), and diet were ass each trimester and compared with neonates (cord or venous blood). More than 50% of the mothers ha nutritional intakes below the recor dietary allowances for zinc, calciu vitamin D, and kilocalories, detern modified version of National Canc Institute Food Questionnaire.

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Schnell, 2003 ¹⁹²	<p>Mother's BPbs were strongly and positively related to neonates BPbs ($p < 0.001$). For the anthropometric measures of maternal nutritional status, variables measuring gain in weight and arm circumference were negatively related to neonate BPbs ($p < 0.001$). Dietary intakes in iron ($p = 0.003$) and vitamin D ($p = 0.038$) were negatively related to neonates BPbs. The effects of zinc varied substantially. Calcium was negatively related to BPbs before controlling for age, education index, etc. ($p = 0.042$), but not after controlling for these variables. Serum ferritin, serum vitamin D, and supplements were not significantly related to BPbs of neonates. African American mothers and newborns have significantly higher BPbs than Caucasians ($p < 0.001$), except in the 2nd trimester.</p>	ND		Fair

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Simon, 1999 ¹⁹³	Ascorbic acid	Cross-sectional study	Probability sample of US population from the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994 without a history of lead poisoning. Adults and youths.	4,213 youths aged 6-16 and 15, 365 adults aged ≥ 17	NA	Measured BPbs and serum ascor levels (by high-performance liquid chromatography). Quantative nut data were collected using 24 hour

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Simon, 1999 ¹⁹³	<p>22 (0.5%) youths had elevated BPbs. 57 (0.4%) adults had elevated BPbs. Serum ascorbic levels ranged from 0-170 micro mol/L, with the mean for the youths 55 micro mol/L and mean for the adults 43 micro mol/L.</p> <p>After controlling for the effects of age, race, sex, income level, and dietary energy, fat, calcium, iron, and zinc intake, youths in the highest serum ascorbic acid tertile had an 89% decreased prevalence of elevated BPbs compared with youths in the lowest serum ascorbic acid tertile (p=0.002). Adults in the highest 2 serum ascorbic acid tertiles had a 65% to 68% decreased prevalence of elevated BPbs compared with adults in the lowest serum ascorbic acid tertile (p=0.03). As a continuous predictor, serum ascorbic acid level was independently associated with decreased BPbs among adults (p<0.001), but not among youths.</p>	ND	<p>Could not include children age 1-5 years because ascorbic acid levels were not measured in NHANES III. No relationship observed between dietary ascorbic acid levels and BPbs, only serum ascorbic acid levels.</p>	NA

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Nutritional Category	Study Design	Population	N	Initial Blood Levels	Intervention Described
Zierold, 2004 ¹⁹⁴	Many, not described	Retrospective Cohort Study with comparison	Data from Wisconsin Childhood Lead Poisoning Prevention Program from 1996-2000. Children ages 0-6.	111,196	mean 5.29 micro g/dL	52,407 children ages 0-6 enrolled Wisconsin Childhood Lead Poisoning Prevention Program's Special Nutrition Program with venous BPbs meas compared with 58,789 all other children ages 0-6 with venous BPbs meas the Wisconsin Prevention Program enrolled in the Special Nutrition P

Abbreviations: BPbs, Blood lead levels; Ca, Calcium; NA, Not applicable; ND, Not described.

TABLE 4. EFFECTS OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Author, Year	Results (Significance levels)	Adverse Effects (NR for absence; ND for failure to describe)	Comments	Quality Rating
Zierold, 2004 ¹⁹⁴	<p>For those in the Special Nutrition Program, mean BPbs declined over the 4 year time period from 7.89 micro g/dL to 5.29 micro g/dL. Average BPb decline of 0.64 micro g/dL per year.</p> <p>For the comparison group, mean BPbs declined over the 4 year time period from 5.51 micro g/dL to 3.70 micro g/dL. Average BPb decline of 0.42 micro g/dL per year. The difference between the groups was not statistically significant (p=0.25).</p> <p>African American children in the Special Nutrition Program BPbs had a significantly quicker decline compared with Caucasian children (p=0.03).</p>	ND		Fair

Abbreviations: BPbs, Blood lead levels; Ca, Calcium; NA, Not applicable; ND, Not described.

TABLE 5. SUMMARY OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Studies	Ascorbic Acid	Calcium	Calories	Carbo-hydrates	Fat	Ferritin	Folate	Folate (serum)	Iron	Multiple, Not Described	Phos-phorus
Randomized Controlled Trials											
Dalton 1997 ¹⁸⁵		NS							NS		NS
Markowitz 2004 ¹⁸⁹		NS									
Sargent 1999 ¹⁹⁰		NS							NS		NS
Prospective Cohort Studies											
Gallicchio 2002 ¹⁸⁶			P	N	P						
Haynes, 2003 ¹⁹⁶		N*									
Lanphear, 2002 ¹⁹⁵		NS							N		
Markowitz 1996 ¹⁵⁷									NS		
Schell 2003 ¹⁹²		NS				NS			N		
Schell 2004 ¹⁹¹		NS				NS			N		
Retrospective Cohort Study (with comparison group)											
Zierold 2004 ¹⁹⁴										NS	
Cross Sectional Studies											
Hammad 1996 ¹⁸⁷									N		
Lee, 2005 ¹²							P	N	P		
Lucas 1996 ¹⁸⁸			P		P						
Simon 1999 ¹⁹³	N										

Abbreviations: P, positive relationship; N, negative/inverse relationship; NS, not significant/no relationship

*Calcium intake was inversely associated with children's blood lead (p=0.03) in a multivariate model that included VDR Fok 1 genotype as an independent variable. No significant effect modification of calcium intake on blood lead by genotype was found (p=0.49). No significant association was observed when the polymorphism was not included (Lanphear, 2002).

TABLE 5. SUMMARY OF NUTRITIONAL INTERVENTIONS ON CHILDREN'S BLOOD LEAD LEVELS

Studies	Protein	Pyrido-xine	Supple- ments	Thiamine	Vitamin C	Vitamin D	Zinc
Randomized Controlled Trials							
Dalton 1997 ¹⁸⁵							
Markowitz 2004 ¹⁸⁹							
Sargent 1999 ¹⁹⁰							
Prospective Cohort Studies							
Gallicchio 2002 ¹⁸⁶					N		
Haynes, 2003 ¹⁹⁶							
Lanphear, 2002 ¹⁹⁵							
Markowitz 1996 ¹⁵⁷							
Schell 2003 ¹⁹²			NS			N (dietary) NS (serum)	Varied
Schell 2004 ¹⁹¹	Varied		NS			NS (serum)	NS
Retrospective Cohort Study (with comparision group)							
Zierold 2004 ¹⁹⁴							
Cross Sectional Studies							
Hammad 1996 ¹⁸⁷							
Lee, 2005 ¹²		P		N			
Lucas 1996 ¹⁸⁸							
Simon 1999 ¹⁹³							

Abbreviations: P, positive relationship; N, negative/inverse relationship; NS, not significant/no relationship

*Calcium intake was inversely associated with children's blood lead (p=0.03) in a multivariate model that included VDR Fok 1 genotype as an independent variable. No significant effect modification of calcium intake on blood lead by genotype was found (p=0.49). No significant association was observed when the polymorphism was not included (Lanphear, 2002).

TABLE 6. SUMMARY OF THE EVIDENCE

Key Question	Findings
<i>Children</i>	
KQ 1. Is there direct evidence that screening for lead results in improved health outcomes (i.e. cognitive changes, behavioral problems, learning disorders)?	There is no direct evidence from controlled studies of screening.
KQ 2. What is the prevalence of elevated lead in children?	The prevalence of blood lead ≥ 10 micro-g/dL among children aged 1-5 years in the U.S. has declined from 9% in 1988-1991 to 1.6% 1999-2002.
Are there population-level risk factors that identify children at higher risk for elevated lead levels?	Population-level risk factors among children include age < 5 years; urban residence; low income; low parental educational attainment; pre-1950 housing; and recent immigration. Mean blood levels among African-American children remain significantly higher than Mexican American children and non-Hispanic whites.
KQ 3. Can screening tests accurately detect elevated blood lead levels?	Blood lead concentration is more sensitive and specific than free erythrocyte protoporphyrin (EP) levels, but can be affected by environmental lead contamination and laboratory analytic variation. In one study of 47,230 suburban and rural children, 4.7% had an elevated EP level, while only 0.6% had elevated BLL. Capillary sampling has false-positive rates of 3-9%, and false-negative rates of 1-8%, compared with venous blood lead levels.
How accurate are questionnaires (or other tools) for risk factor assessment at various blood lead levels?	The sensitivity and specificity of questionnaires vary considerably with the prevalence of EBLL in the population surveyed and the cutoff BLL (10 vs. 15 micro-g/dL). One study found that rental status, lead-contaminated floor dust, and poor housing condition were associated with EBLL, suggesting that housing characteristics can be used to identify homes where a lead hazard may exist before or during occupancy.

TABLE 6. SUMMARY OF THE EVIDENCE (continued)

Key Question	Findings
<i>Children</i>	
What is the optimal frequency for screening? What is the optimal frequency for repeat testing?	Not addressed in this review.
KQ5: Do interventions for elevated lead levels result in improved health outcomes or lead levels?	We identified no evidence that treatment, lead abatement, or education improved neurocognitive outcome in asymptomatic children with mildly-moderately increased lead levels. In one trial of succimer there was no benefit or slight harm. Some interventions have small, inconsistent, or unsustained effects on lead levels in high-risk children.
KQ4, KQ6 What are the adverse effects of screening and treatment?	See text.
KQ7: What are cost effectiveness issues?	Not addressed in this review.

TABLE 6. SUMMARY OF THE EVIDENCE (continued)

Key Question	Findings
<i>Pregnant Women</i>	
KQ 1. Is there direct evidence that screening in asymptomatic pregnant women for lead results in improved health outcomes?	There is no direct evidence from controlled studies of screening that screening improves maternal hypertension, cognitive changes in offspring or perinatal outcomes.
KQ 2. What is the prevalence of elevated lead in pregnant women?	In 1992, two large surveys of low-income pregnant women found 0% and 6% with blood levels >15 micro-g/dL. A longitudinal study of pregnant women in Boston found that umbilical cord blood levels declined 82% between 1980 and 1990.
Are there population-level risk factors that identify pregnant women at higher risk for elevated lead levels (i.e., geography, racial/ethnicity, SES, age)?	Ethnic background, country of origin, and immigrant status of birth mothers have been shown to be associated with prenatal lead exposure in newborns. Cigarette smoking, maternal age, and alcohol intake have been found to increase umbilical cord blood lead levels.
KQ 3. Can screening tests accurately detect elevated blood lead levels?	See KQ 3. in Children, above.
How accurate are questionnaires (or other tools) for risk factor assessment at various blood lead levels?	We found one study of a 4-question prenatal survey developed by the CDC that had a sensitivity of 75.7%, and a negative predictive value of 93.1%.
What is the optimal frequency for screening? What is the optimal frequency for repeat testing?	Not addressed in this review.
KQ5: Do interventions for elevated lead levels result in improved health outcomes?	We identified no evidence that treatment, lead abatement, or education improved neurocognitive outcome in asymptomatic children with mildly-moderately increased lead levels. In one trial of succimer there was no benefit or slight harm.
KQ4, KQ6 What are the adverse effects of screening and treatment?	See text.

APPENDIX 1: CRITERIA FOR GRADING THE INTERNAL VALIDITY OF INDIVIDUAL STUDIES

The Methods Work Group for the Third U.S. Preventive Services Task Force (USPSTF) developed a set of criteria by which the quality of individual studies could be evaluated. At its September 1999 quarterly meetings, the USPSTF accepted the criteria and definitions of quality categories relating to internal validity.

Presented below are a set of minimal criteria for each study design and a general definition of three categories— “good,” “fair,” and “poor”. These specifications are not meant to be rigid rules but rather are intended to be general guidelines, and individual exceptions, when explicitly explained and justified, can be made. In general, a “good” study is one that meets all criteria well. A “fair” study is one that does not meet (or it is not clear that it meets) at least one criterion but has no major limitations. “Poor” studies have at least one major limitation.

Systematic Reviews

Criteria:

- Comprehensiveness of sources considered/search strategy used
- Standard appraisal of included studies
- Validity of conclusions
- Recency and relevance are especially important for systematic reviews

Definition of ratings from above criteria:

Good: Recent, relevant review with comprehensive sources and search strategies; explicit and relevant selection criteria; standard appraisal of included studies; and valid conclusions.

Fair: Recent, relevant review that is not clearly biased but lacks comprehensive sources and search strategies.

Poor: Outdated, irrelevant, or biased review without systematic search for studies, explicit selection criteria, or standard appraisal of studies.

APPENDIX 1: CRITERIA FOR GRADING THE INTERNAL VALIDITY OF INDIVIDUAL STUDIES (continued)

Case Control Studies

Criteria:

- Accurate ascertainment of cases
- Nonbiased selection of cases/controls with exclusion criteria applied equally to both
- Response rate
- Diagnostic testing procedures applied equally to each group
- Measurement of exposure accurate and applied equally to each group
- Appropriate attention to potential confounding variable

Definition of ratings based on criteria above:

Good: Appropriate ascertainment of cases and nonbiased selection of case and control participants; exclusion criteria applied equally to cases and controls; response rate equal to or greater than 80 percent; diagnostic procedures and measurements accurate and applied equally to cases and controls; and appropriate attention to confounding variables.

Fair: Recent, relevant, without major apparent selection or diagnostic work-up bias but with response rate less than 80 percent or attention to some but not all important confounding variables.

Poor: Major selection or diagnostic work-up biases, response rates less than 50 percent, or inattention to confounding variables.

Randomized Controlled Trials and Cohort Studies

Criteria:

- Initial assembly of comparable groups
 - for RCTs: adequate randomization, including first concealment and whether potential confounders were distributed equally among groups
 - for cohort studies: consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts
- Maintenance of comparable groups (includes attrition, cross-overs, adherence, contamination)
- Important differential loss to followup or overall high loss to follow-up
- Measurements: equal, reliable, and valid (includes masking of outcome assessment)
- Clear definition of interventions
- Important outcomes considered

APPENDIX 1: CRITERIA FOR GRADING THE INTERNAL VALIDITY OF INDIVIDUAL STUDIES (continued)

- Analysis: adjustment for potential confounders for cohort studies, or intention to treat analysis for RCTs.

Definition of ratings based on above criteria:

Good: Meets all criteria: comparable groups are assembled initially and maintained throughout the study (followup at least 80 percent); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; important outcomes are considered; and appropriate attention to confounders in analysis. In addition, for RCTs, intention to treat analysis is used.

Fair: Studies will be graded “fair” if any or all of the following problems occur, without the fatal flaws noted in the “poor” category below: Generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred in followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for. Intention-to-treat analysis is done for RCTs.

Poor: Studies will be graded “poor” if any of the following fatal flaws exists: groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied at all equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. For RCTs, intention-to-treat analysis is lacking.

Diagnostic Accuracy Studies

Criteria:

- Screening test relevant, available for primary care, adequately described
- Study uses a credible reference standard, performed regardless of test results
- Reference standard interpreted independently of screening test
- Handles indeterminate results in a reasonable manner
- Spectrum of patients included in study
- Sample size
- Administration of reliable screening test

Definition of ratings based on above criteria:

Good: Evaluates relevant available screening test; uses a credible reference standard; interprets reference standard independently of screening test; reliability of test assessed; has few or handles indeterminate results in a reasonable manner;

APPENDIX 1: CRITERIA FOR GRADING THE INTERNAL VALIDITY OF INDIVIDUAL STUDIES (continued)

includes large number (more than 100) broad-spectrum patients with and without disease.

Fair: Evaluates relevant available screening test; uses reasonable although not best standard; interprets reference standard independent of screening test; moderate sample size (50 to 100 subjects) and a “medium” spectrum of patients.

Poor: Has fatal flaw such as: uses inappropriate reference standard; screening test improperly administered; biased ascertainment of reference standard; very small sample size of very narrow selected spectrum of patients.